Your HIV Questions, Met With Care.

HIV (Human Immunodeficiency Virus) is the virus itself. AIDS (Acquired Immunodeficiency Syndrome) is a specific clinical diagnosis given when HIV has severely damaged the immune system — specifically when CD4 counts drop below 200 cells/mm³, or when certain AIDS-defining illnesses develop.

With modern treatment, most people living with HIV never progress to AIDS. Starting ART early and taking it consistently keeps the immune system healthy. AIDS is not an inevitable outcome of HIV — it is a sign that HIV went undetected or untreated for too long.

Even if someone was previously diagnosed with AIDS, treatment can substantially restore immune function. The AIDS diagnosis technically remains on their medical record, but it no longer defines their health trajectory.

HIV is transmitted through specific body fluids: blood, semen (including pre-seminal fluid), rectal fluids, vaginal fluids, and breast/chest milk. Transmission requires those fluids to enter another person’s bloodstream through a mucous membrane, broken skin, or direct injection.

Main routes: sexual contact (primarily anal sex, then vaginal sex, very rarely oral sex), sharing needles or syringes, parent-to-child transmission during pregnancy, birth, or breast/chestfeeding, and (extremely rare in the U.S. today) blood transfusions.

HIV is not transmitted through casual contact, hugging, kissing, coughing, sneezing, shared food or drinks, toilet seats, swimming pools, or mosquito bites.

Critically: a person on effective treatment with an undetectable viral load cannot sexually transmit HIV. This is U=U — see the U=U category below for the full science.

HIV testing is available at HIV clinics, Planned Parenthood, health departments, community health centers, pharmacies, and by mail. Many locations offer free, confidential testing — and mail-in test kits can be ordered from home, sometimes free of charge.

Test types:
• 4th-generation antigen/antibody (lab) — the clinical standard. Detects both the p24 antigen and HIV antibodies. Highly accurate from 18–45 days after exposure.
• Antibody-only tests — blood or oral fluid. Take 23–90 days to become fully accurate.
• NAT/RNA tests — detect the virus directly. Accurate as early as 10–33 days. Not routine due to cost, but useful in specific situations.
• At-home tests (OraQuick, mail-in) — oral fluid or fingerstick, results in 20 minutes or a few days. Less sensitive very early on.

Use our Florida care locator to find free testing near you.

The window period is the time between HIV exposure and when a test can reliably detect infection. Testing too soon can produce a false negative — not because the test is broken, but because the body hasn’t produced enough of what the test looks for yet.

Window periods by test:
• 4th-generation lab test: 18–45 days (99% accurate by day 45)
• Antibody-only test: 23–90 days
• NAT/RNA test: 10–33 days
• At-home oral test: up to 90 days

The CDC recommends testing at 45 days after a possible exposure using a 4th-generation test, with a follow-up at 90 days if negative.

If you were potentially exposed within the last 72 hours, do not wait to test — ask about PEP right away. Every hour matters, and PEP is time-critical.

These are the two most important numbers in HIV care — and they measure different things:

CD4 count measures the number of CD4 T-cells (immune cells) per cubic millimeter of blood. HIV specifically attacks these cells. A typical healthy range is 500–1,500. Below 200 is where an AIDS diagnosis is made. On effective treatment, CD4 counts typically rise over months and years as the immune system recovers.

Viral load measures the amount of HIV RNA in the blood — essentially, how much virus is actively circulating. The goal of treatment is to suppress viral load to “undetectable” (below the level the test can measure, typically fewer than 20–50 copies/mL depending on the assay).

Once you’re established on treatment, viral load is the most important number to watch. CD4 count matters early on and for people with advanced disease, but for most people on stable ART, ongoing viral load suppression is the primary goal.

HIV has three general phases, and each one looks different:

Acute HIV (2–4 weeks after exposure): Many people experience flu-like symptoms — fever, swollen lymph nodes, sore throat, rash, muscle aches, headache. This is often mistaken for the flu, mono, or a bad cold. It resolves on its own in a few weeks, but the virus is still there.

Chronic HIV (years): HIV can be present for years with no symptoms at all while quietly damaging the immune system. This is why regular testing matters — you cannot rely on how you feel to know your status.

Advanced HIV / AIDS: When the immune system is severely compromised, opportunistic infections and other serious illnesses appear. Symptoms vary widely depending on what infection is present.

The takeaway: you cannot know your HIV status by how you feel. Testing is the only way to know.

Not yet — for most people. A small number of individuals have achieved apparent HIV cures following stem cell transplants performed to treat cancer (the “Berlin Patient,” “London Patient,” and a handful of others). But those procedures carry significant risk and are not a scalable treatment approach.

Researchers are actively pursuing broadly neutralizing antibodies, gene editing (including CRISPR-based approaches), “kick and kill” strategies that target the viral reservoir, and long-acting treatments that may eventually induce remission. Progress is real and accelerating.

The honest answer for today: HIV is not curable with standard treatment, but it is highly manageable. Lifelong ART keeps the virus suppressed and allows people to live full, healthy lives. The goal of cure research is to eventually remove the need for lifelong treatment — and that goal feels closer than it has ever been.

No. HIV is not transmitted through everyday contact. You cannot get HIV from working with, going to school with, sharing a bathroom with, or living with someone who has HIV.

HIV is not spread through: shared air, shared dishes or utensils, handshakes, hugs, coughing, sneezing, sweat, tears, saliva, toilet seats, swimming pools, or any other ordinary contact. There is no medical reason to avoid everyday contact with people living with HIV.

Policies that exclude people living with HIV from schools, workplaces, healthcare settings, or shared housing are discriminatory and scientifically unfounded.

Without treatment, HIV progresses through three stages over years — though the timeline varies widely:

Stage 1 — Acute infection: First 2–4 weeks. Flu-like symptoms in many people. Viral load is very high and highly transmissible. Often mistaken for flu or mono.

Stage 2 — Chronic infection: Can last a decade or more with no symptoms. HIV is active but slower. CD4 count gradually declines. Many people in this stage don’t know they have HIV.

Stage 3 — AIDS: CD4 count drops below 200 or AIDS-defining illnesses appear. Without treatment, survival after an AIDS diagnosis is typically 3 years or less.

With treatment started at any stage, this progression stops and often reverses. Starting earlier produces better long-term outcomes.

HIV stigma has deep historical roots. The U.S. epidemic first became visible in communities that were already marginalized — gay men, people who inject drugs, sex workers, Haitian immigrants — and was quickly framed by politicians, religious leaders, and media as a moral consequence rather than a public health crisis.

The Reagan administration’s silence for years into the epidemic sent a clear message: these lives were expendable. That message landed in a society already primed to stigmatize the communities most affected. HIV became associated not just with illness, but with moral failure, “lifestyle choices,” and otherness.

Decades later — even with dramatically changed medical reality — much of that original stigma still lingers, sometimes in the very communities most affected, showing up as internalized shame. Dismantling it takes both accurate information and honest reckoning with where it came from.

Yes. FDA-authorized HIV self-tests are reliable when used exactly as directed and after their window period. They are a private, useful way to learn your status, especially when getting to a clinic is difficult.

Most rapid self-tests look for HIV antibodies, so they can miss a very recent exposure. A negative result is most reassuring once the kit’s full window period has passed; if the exposure was recent, ask a clinic which test and timing make sense. A positive self-test is a screening result and must be confirmed with a laboratory test.

If you test positive, you do not have to carry that result alone. Contact an HIV clinic, health department, or the number in the test kit for confirmatory testing and a connection to care.

No. HIV is not transmitted through saliva, tears, sweat, urine, or feces. You cannot get HIV from:

• Kissing (including deep kissing) — saliva contains enzymes that inactivate HIV
• Sharing food, drinks, utensils, cups, or straws
• Toilet seats, doorknobs, gym equipment, swimming pools
• Mosquito or insect bites — HIV cannot replicate in insects
• Hugging, shaking hands, sneezing, coughing
• Sweat during sex or contact sports

HIV requires direct contact between infected bodily fluids (blood, semen, pre-seminal fluid, rectal fluid, vaginal fluid, or breast milk) and either a mucous membrane, damaged tissue, or the bloodstream via a needle. Saliva doesn’t carry enough virus to transmit — the CDC has never documented a case of HIV transmission through kissing, even deep kissing.

The only exception ever considered was one poorly-documented 1997 case involving severe bleeding gums on both partners simultaneously — and even that had confounding factors and has never been replicated in 30 years of study.

U=U — Undetectable = Untransmittable — means that a person living with HIV who is on treatment and has an undetectable viral load cannot sexually transmit the virus to an partner without HIV.

This is not a theory, a probability, or a hope. It is confirmed by three large clinical trials — PARTNER, PARTNER 2, and Opposites Attract — that followed thousands of serodifferent couples (one living with HIV, one without HIV) over years of condomless sex. Result: zero linked HIV transmissions where the partner living with HIV was virally suppressed.

U=U is endorsed by the CDC, WHO, NIH, and every major HIV medical organization. It is settled science.

Staying undetectable comes down to one thing: taking your HIV medication consistently. For most people on effective ART, viral load suppression is maintained indefinitely as long as they continue treatment.

Regular viral load testing — typically every 3–6 months on stable treatment — confirms you remain suppressed. If viral load starts to rise, your provider will look into why (missed doses, resistance, absorption issues, drug interactions) and adjust the plan accordingly.

If a daily pill is a challenge, long-acting injectable ART is now an option for many people. Cabotegravir + rilpivirine (Cabenuva) is given every 1 or 2 months, and newer long-acting regimens are extending the interval further. These options remove the daily pill and maintain the same viral suppression.

This is one of the most painful disconnects in HIV today. The science of U=U is clear — an undetectable person poses zero risk of sexually transmitting HIV. Yet many HIV criminalization laws, including Florida’s, were written before this science existed and have not been updated to reflect it.

Under Florida law, viral suppression is not formally recognized as a complete legal defense. That means a person can be prosecuted even when they were undetectable and posed no actual transmission risk. See the Rights & Legal section for the full breakdown of what the statute requires.

Cultural stigma operates on a similar lag. Many people’s beliefs about HIV are still shaped by 1980s and 1990s coverage, and haven’t caught up with the last two decades of science. U=U advocacy is partly about pushing law and culture to catch up with what medicine already knows.

The U=U evidence base comes primarily from studies of anal and vaginal sex. Oral sex already carries very low HIV transmission risk even without viral suppression, so the PARTNER studies weren’t specifically designed to measure that route.

What we can say: oral sex has always been very low risk for HIV transmission, and an undetectable viral load further reduces any theoretical risk. No documented HIV transmissions via oral sex have been found in studies of virally suppressed people.

The scientific consensus is that U=U covers oral sex in practice — it just wasn’t the focus of the landmark trials because baseline risk was already so low.

Medically, no. If you are consistently undetectable, your partner’s HIV risk from you is zero. The PARTNER studies confirmed this across tens of thousands of condomless sex acts with zero linked transmissions.

Whether to use additional prevention is a personal choice, not a medical requirement. Some couples choose PrEP or condoms for peace of mind, for STI protection, or while waiting for initial suppression after starting treatment. Others, once fully informed about U=U, rely on viral suppression alone.

Both approaches are valid. What matters is that both partners understand the science and make the decision together with accurate information — not out of fear or pressure.

For many people living with HIV, reaching undetectable is one of the most emotionally significant milestones of the whole journey. Here’s what it changes — medically and personally:

Medically: Viral suppression means HIV is no longer actively damaging your immune system. CD4 counts stabilize or recover. Long-term health outcomes improve dramatically. Chronic inflammation — the driver of many HIV-associated complications — drops significantly.

For relationships and sex: U=U means you cannot sexually transmit HIV to a partner. That removes a layer of fear and negotiation from intimacy that many people describe as transformative. Sex can be about pleasure and connection again, not just risk management.

Emotionally: Many people describe “undetectable” as the word “manageable” made concrete. It shifts HIV from an abstract threat to a condition genuinely under control.

What doesn’t change: the ongoing need for regular care and medication. But the daily psychological weight lifts significantly for most people once they’re there.

Yes — and this is actually where the strongest evidence lives. The PARTNER 2 study focused specifically on gay and bisexual men, following 972 serodifferent male couples over several years with a cumulative 77,000 condomless acts of anal sex while the partner living with HIV was virally suppressed. The result: zero linked HIV transmissions.

This is the most direct evidence that U=U holds for anal sex — both receptive and insertive. The science is unambiguous on this point.

Some people have heard that anal sex carries "higher risk" than other routes — and that's true in the absence of suppression. But with an undetectable viral load, the route doesn't matter: the risk is zero.

This is one of the most common and painful experiences for PLHIV in relationships — sharing something that is scientifically settled and having it met with doubt or fear.

What tends to help: Share primary sources, not just your word. The CDC's U=U page, the PARTNER study summary, and the Prevention Access Campaign consensus statement carry more weight than a personal explanation alone. Offer to attend an appointment with your HIV provider together so they can answer questions directly from a clinical authority.

What to name honestly: A partner's skepticism about U=U after seeing the evidence may reflect deeper fear, stigma, or discomfort with HIV that isn't really about the science. That's worth a direct conversation — "What would it take for you to feel safe?" — rather than continuing to debate evidence.

What you can't do: Force someone to accept a fact. If a partner continues to treat you as dangerous after being given accurate information, that's information about the relationship — not just about their knowledge of HIV.

Almost certainly no. The landmark studies that established U=U (PARTNER, PARTNER2, Opposites Attract, HPTN 052) all allowed for the small blips that are normal during long-term treatment. Across those studies, zero transmissions occurred through condomless sex during hundreds of thousands of sex acts — including through periods when participants had transient blips.

The clinical threshold for U=U is a viral load under 200 copies/mL on stable treatment. A “blip” is defined as a single reading between 50–200 (sometimes up to 500) that returns to undetectable at the next test, with no change in medication. Blips reflect normal biological variation, not treatment failure, and don’t make you infectious.

What would raise real concern: two consecutive viral loads above 200, or a single reading over 1,000. Those aren’t blips — they’re a signal to talk with your provider about adherence, drug levels, or possible resistance.

Bottom line: occasional blips do not break U=U. If you’re worried after a specific lab result, talk to your provider — but don’t panic, and don’t stop having the sex life you want.

Most people reach an undetectable viral load within 3 to 6 months of starting effective ART. Many modern regimens — particularly integrase inhibitor-based combinations like bictegravir (Biktarvy) and dolutegravir (Triumeq, Dovato) — drop viral load dramatically within the first 4–8 weeks.

Your provider will check viral load at about 4–8 weeks after starting, then again at 3 months, then every 3–6 months once you’re suppressed. Consistency is what drives suppression — missing doses early on can slow the process and raise the risk of resistance.

An occasional missed dose is not a catastrophe — but it’s worth handling correctly.

General rule: If less than half the time until your next dose has passed, take the missed dose as soon as you remember. If it’s almost time for your next dose, skip the missed one and go back to your regular schedule. Never double up.

Specifics vary by medication — ask your pharmacist or HIV provider for guidance on your exact regimen.

If you’re struggling with adherence for any reason — side effects, cost, mental health, substance use, an unstable living situation — tell your provider. This is one of the most common conversations they have, and there is no judgment attached. Solutions exist, including simpler once-daily regimens and long-acting injectables that eliminate the daily pill entirely.

With current standard ART, yes — treatment is lifelong. HIV integrates into your DNA and lives in cellular reservoirs that current drugs suppress but cannot eliminate. If treatment stops, viral load rebounds, usually within weeks.

That said, the field is moving quickly. Research into long-acting treatments, functional cure strategies (where the immune system controls HIV without daily medication), and reservoir-targeting approaches is accelerating every year. A small number of documented HIV cures have occurred following stem cell transplants performed for cancer treatment — a high-risk procedure that isn’t a scalable approach for most people, but a proof of concept that a cure is biologically possible.

“Lifelong treatment” today can mean a single once-daily pill or long-acting treatment options that may reduce how often medication is needed — a completely different reality than 20 years ago, and likely to keep getting simpler.

Instead of a daily pill, long-acting injectables are given by a healthcare provider every 1–6 months. For many people, this is life-changing.

Currently approved for HIV treatment:
• Cabenuva (cabotegravir + rilpivirine) — monthly or every-2-month injections. The first complete long-acting ART regimen. Approved for virally suppressed adults with no relevant resistance to either drug.
• Sunlenca (lenacapavir) — injections every 6 months, taken in combination with other ART. Approved for people with multi-drug resistant HIV whose current regimen isn’t working. (Lenacapavir is also approved separately for prevention as Yeztugo.)

Injectables aren’t for everyone — they require you to be virally suppressed first, to keep every appointment, and to have a provider set up to administer them. But if daily pills are hard for any reason — adherence, stigma, mental health — ask your HIV provider whether you’re a candidate. Our Florida care locator can help you find a provider offering injectables.

Substance use is common and manageable in HIV care. Here’s what to know:

Cannabis: No significant direct drug interactions with most modern ART. Fine to use if it’s working for you — just be honest with your provider so they have the full picture.
Alcohol: Moderate use is generally manageable. Heavy chronic use stresses the liver (which processes ART) and can undermine adherence. If you want to cut back or stop, support is available — without judgment.
Stimulants (meth, cocaine): Can create real adherence challenges and may accelerate certain neurocognitive effects for people living with HIV. Harm reduction and peer support programs can help — you don’t have to be sober to be in HIV care.
Opioids and injection drug use: The main HIV-related concern is sharing needles. Never share; use new equipment every time; keep naloxone (Narcan) accessible. Buprenorphine (Suboxone) doesn’t significantly interact with most modern ART, so medication-assisted treatment is fully compatible.

The most important thing: be honest with your HIV provider. They’ve heard it all, they’re not going to fire you as a patient, and they need accurate information to give you accurate care.

Modern HIV regimens are dramatically better tolerated than the drugs of the 1990s and early 2000s. Most people starting treatment today experience minimal or no lasting side effects.

Common early side effects (often resolve within a few weeks): nausea, headache, fatigue, and loose stools. Taking your medication with food can help with nausea for some regimens.

Medication-specific effects worth knowing: Efavirenz (older, less commonly used now) can cause vivid dreams and mood changes, especially early on. Dolutegravir and bictegravir (current first-line drugs) are generally well-tolerated; some people report mild insomnia, headache, or weight changes. Tenofovir DF (TDF) in older regimens could affect kidney function and bone density over time — tenofovir AF (TAF), used in most current regimens, has a much better profile.

If side effects are affecting your quality of life or making it hard to stay on treatment, tell your provider. There are multiple effective regimen options, switching is usually straightforward, and finding the right fit matters — you shouldn’t have to white-knuckle through discomfort.

HIV replicates fast and mutates constantly. When drug levels in the body drop too low — from missed doses, poor absorption, drug interactions, or other factors — HIV can mutate in ways that make certain drugs less effective or fully ineffective. That’s drug resistance.

Resistance is not a crisis. It’s a manageable clinical situation. HIV providers run resistance tests (genotype and, when needed, phenotype testing) to identify which mutations are present and which drugs will still work. Thanks to the range of drug classes now available — integrase inhibitors, protease inhibitors, NNRTIs, NRTIs, entry inhibitors, capsid inhibitors — switching to an effective regimen is possible for the vast majority of people, even those with significant resistance history.

The best way to prevent resistance in the first place is consistent adherence. Modern integrase inhibitor-based regimens like Biktarvy and Dovato have a high genetic barrier to resistance, meaning it takes many more missed doses to develop resistance than with older drug classes. That’s one reason today’s treatment is so much more forgiving than the regimens people started on in the 1990s.

Most people starting modern ART have a much smoother experience than they expect. Here’s a rough timeline:

First 2–4 weeks: Mild side effects are possible — nausea, headache, fatigue, or loose stools. These usually resolve on their own. Taking your medication with food can help with nausea for many regimens.

4–8 weeks: Your provider will check your viral load for the first time. Many people see dramatic drops already — sometimes from hundreds of thousands of copies down to undetectable within a month or two.

3–6 months: Most people reach full viral suppression. CD4 count begins recovering. Many people say they feel better than they did before starting treatment — because the virus is no longer driving chronic inflammation in the body.

If side effects are significant or hurting your quality of life, tell your provider right away. Multiple effective first-line options exist, and finding the right fit matters. There’s no prize for suffering through a regimen that isn’t working for you.

The honest answer: modern ARTs are far safer long-term than older drugs, but a few considerations exist for people on decades of treatment.

Kidney function: Tenofovir DF (TDF), used in older regimens, had some kidney effects for a small number of people over time. Tenofovir AF (TAF), now standard, has a much better kidney profile. People on long-term ART have kidney function monitored routinely.

Bone density: Both HIV itself and some older ARTs can reduce bone density over time. Calcium, vitamin D, weight-bearing exercise, and (when indicated) bone-density screening are part of routine care for long-term survivors and aging people living with HIV.

Cardiovascular and metabolic effects: Some older drug classes — especially certain protease inhibitors — affected lipids and metabolism. Modern regimens have much cleaner profiles, but HIV-related chronic inflammation still elevates cardiovascular risk somewhat, independent of the medications. Blood pressure, cholesterol, and diabetes screening are standard.

The bottom line: the risks of untreated HIV vastly outweigh the risks of modern ART. Annual monitoring catches issues early, and many long-term survivors are living well into their 70s and beyond.

Yes — with some planning. People living with HIV travel internationally all the time.

Medication supply: Bring more medication than you need — at least a week extra — in your carry-on, never checked luggage. Keep medications in original labeled packaging so customs officers can identify them. For longer trips, ask your provider or pharmacist about an extended supply.

Entry restrictions: A shrinking but still real list of countries have HIV-related entry restrictions or require HIV testing for long-term visas or work permits. Check hivtravel.org for current country-by-country rules before you book.

Time zones and dosing: If you’re crossing many time zones, ask your provider how to adjust your dosing schedule. For once-daily regimens, shifting the time gradually over a few days works well for most people.

Heat sensitivity: Most modern ARTs are stable at room temperature for travel periods. If you’re heading to very hot climates for extended stays, check the storage requirements for your specific medications.

The same core ART regimens are used across genders, but some sex- and gender-specific considerations matter:

Pregnancy: ART during pregnancy is essential — it protects the parent’s health and reduces the chance of parent-to-child transmission to near zero. Some specific ARTs are preferred or avoided during pregnancy based on the latest safety data. Anyone living with HIV who is pregnant or planning pregnancy should discuss their regimen with their HIV provider and an OB with HIV experience.

Drug interactions with hormonal contraception and gender-affirming hormone therapy: Some older ARTs (particularly certain NNRTIs and protease inhibitors) can affect hormone levels in contraceptives or estrogen/testosterone regimens. Modern integrase inhibitor regimens generally have fewer interactions, but it’s always worth reviewing with your HIV provider — especially at every regimen change.

Dosing and side effect profiles: Some research suggests women may experience different side effect profiles with certain ARTs than men do, and clinical trials have historically underenrolled women. If you’re experiencing side effects your provider seems to be dismissing, advocate for yourself — or seek a second opinion. Your experience is data.

Ideally, yes — or at least coordinating closely with your mental health provider. HIV care and mental health care are deeply intertwined. Depression and anxiety affect adherence. Adherence affects viral suppression. Viral suppression affects long-term health. The connections are direct, and the best HIV clinics recognize this.

The strongest HIV care is integrated care: a team that includes your HIV physician, a case manager, a mental health provider (therapist or psychiatrist), and ideally a pharmacist. Ryan White-funded clinics often have this model built in, and it’s worth asking about when choosing where to get care.

If your current HIV provider doesn’t ask about your mental health, bring it up yourself — they should be. And if your mental health provider doesn’t know you’re living with HIV, consider telling them. It’s relevant context for everything from therapy work to medication decisions.

A viral blip is one small, detectable viral-load result after you have been suppressed, followed by a return to suppression on the next test. It is common enough to have a name and, by itself, usually does not mean your medication has stopped working.

Lab variation, a recent illness or vaccination, and other short-term factors can contribute. Do not stop or change your medication on your own. Take it as prescribed and ask your HIV provider when they want to repeat the test.

What deserves a closer look is a pattern of rising or repeatedly detectable results, especially a confirmed viral load of 200 copies/mL or more. Your care team can review doses, interactions, absorption, and resistance testing if needed.

“Medication tourism” is buying HIV drugs from cheaper markets — usually India, Thailand, Mexico, or Canada — either by traveling there or ordering online. The appeal is real: the same drug that costs $3,500/month in the US can cost $50–$100 elsewhere.

The risks are also real:

• Counterfeit medication. WHO estimates 10% of medicines in low- and middle-income countries are substandard or falsified. HIV drugs are a top counterfeit target. A pill that looks identical may contain the wrong dose, wrong drug, or no active ingredient — and resistance can develop in weeks.
• Legal risk. The US technically prohibits importing prescription drugs for personal use, though enforcement against small personal-use quantities is rare. Customs can seize your shipment.
• No continuity of care. If you have a side effect, drug interaction, or resistance question, the pharmacist who sold you the meds abroad isn’t available for follow-up.

Before you consider it, exhaust the domestic options: ADAP (free HIV meds in Florida if you qualify), Ryan White programs, manufacturer patient assistance programs (Gilead Advancing Access, ViiV Patient Assistance), and 340B pharmacies at Ryan White clinics can bring your out-of-pocket cost to $0 for most people, even without insurance.

With consistent use, oral PrEP reduces the risk of getting HIV from sex by up to 99% and from injection drug use by at least 74%. Missed doses reduce protection, but the modern drugs are more forgiving than the original studies suggested.

Injectable PrEP raises the bar further:
• Apretude (cabotegravir, every 2 months) — shown superior to daily oral Truvada in the HPTN 083 and 084 trials.
• Yeztugo (lenacapavir, twice-yearly injection) — the PURPOSE 1 and PURPOSE 2 trials showed near-100% efficacy, with zero infections in several trial arms. A landmark result, and now FDA-approved for prevention.

PrEP does not protect against other STIs. Regular STI testing every 3 months is standard on PrEP — and one of the quiet benefits of being on it.

Truvada oral: Roughly 7 days for receptive anal sex, about 21 days for receptive vaginal/front hole sex, and around 7 days for insertive sex.
Descovy oral: Similar timing to Truvada for anal sex. Not FDA-approved for people at risk through receptive vaginal/front hole sex, because that population wasn’t adequately studied in the approval trials.
Apretude (cabotegravir injectable): Protective shortly after the first injection. A two-injection initiation protocol (one month apart) is standard before reliance on the every-2-month schedule.
Yeztugo (lenacapavir, twice-yearly): Follows a specific initiation protocol combining oral loading doses with the first injection — your provider will walk you through it.

PEP (Post-Exposure Prophylaxis) is emergency HIV prevention medication started after a possible exposure — a broken condom, a sexual assault, a needlestick, or any other event with real HIV risk. It’s not a substitute for PrEP; it’s an emergency intervention.

PEP must be started within 72 hours of the exposure, and the sooner the better — ideally within a few hours. After 72 hours, it is not effective. If your regular clinic is closed, go to an emergency room, urgent care, or a Ryan White clinic — do not wait until Monday.

PEP is a 28-day course of medication. After you complete it, ask your provider whether transitioning to PrEP makes sense if there’s ongoing risk in your life.

DoxyPEP is a single 200mg dose of doxycycline taken within 72 hours after condomless sex to reduce bacterial STIs — syphilis, chlamydia, and (to a lesser extent) gonorrhea. It does not prevent HIV.

Clinical trials showed a 65–87% reduction in bacterial STI incidence in gay and bisexual men and transgender women. The CDC currently recommends considering DoxyPEP for gay, bisexual, and other men who have sex with men, and transgender women, who have had a bacterial STI in the past 12 months.

Two concerns to weigh with your provider: antibiotic resistance (especially in gonorrhea, which is developing broad resistance) and long-term microbiome effects. Ask your PrEP or HIV provider whether it makes sense for you personally.

No. PrEP protects against HIV only — not syphilis, gonorrhea, chlamydia, herpes, HPV, or any other STI. That’s why regular STI testing every 3 months is a standard part of PrEP care.

One quiet upside: the quarterly STI screening built into PrEP care catches infections much earlier than most people would otherwise test. People on PrEP tend to have better overall sexual health awareness than those outside of regular care, precisely because they’re seen every three months.

Yes, absolutely. Oral PrEP reduces HIV risk from injection drug use by at least 74% when taken consistently. Injectable PrEP is especially helpful when daily pill adherence is a challenge, whether that’s from active use, mental health, or an unstable living situation.

Many syringe service programs (SSPs) now offer PrEP referrals or on-site prescribing. Other harm reduction strategies that stack with PrEP: never share needles or works, use new equipment every time, and keep naloxone (Narcan) accessible for yourself and the people around you.

Use our Florida care locator to find harm reduction and PrEP services near you.

Most people on PrEP tolerate it very well. Side effects, when they happen, are usually mild and temporary.

Truvada (TDF/FTC): Some people experience mild nausea, headache, or fatigue in the first few weeks. These typically resolve. Long-term, TDF has some effect on kidney function and bone density in a small number of people, which is why kidney labs and occasional bone monitoring are part of routine PrEP follow-up.

Descovy (TAF/FTC): Similar short-term tolerability to Truvada, with a better kidney and bone profile. Some people report modest weight gain.

Apretude (cabotegravir injectable): Injection site reactions — soreness or swelling at the injection site — are the most common side effect and typically improve over the first several doses.

Yeztugo (lenacapavir): Injection site reactions are the main side effect. Some mild systemic effects (headache, nausea) can occur with the loading doses.

If side effects are bothersome, talk to your PrEP provider. Switching between formulations is usually straightforward.

Cost should not be a barrier to PrEP. Several programs make it low- or no-cost:

Ready, Set, PrEP: A federal program that provides free Truvada or Descovy to uninsured Americans who qualify. Apply at getyourprep.com.

Gilead’s Advancing Access program: Free Truvada, Descovy, or Yeztugo for uninsured patients below income thresholds. Copay assistance for insured patients.

ViiV Compass Initiative: Covers cabotegravir (Apretude) for uninsured or underinsured patients.

Florida ADAP: Can cover PrEP for income-eligible Floridians who meet ADAP’s enrollment criteria. A Ryan White case manager can help you apply.

Insurance: Most private insurance and Medicaid plans cover PrEP. Under the ACA, most plans are required to cover PrEP with no cost-sharing — no copay, no deductible — because it’s rated an “A” preventive service by the U.S. Preventive Services Task Force.

Use our Florida care locator to find PrEP providers; many can help you navigate cost assistance during your first visit.

When used correctly and consistently, condoms reduce HIV transmission risk by approximately 70–90% for receptive anal sex and higher for other sexual routes. “Correct and consistent” means every time, from start to finish, with the right size, adequate lubrication, and no breakage.

Real-world effectiveness is lower than the theoretical maximum because of inconsistent use, improper use, and breakage. That’s why combination prevention — condoms plus PrEP, or condoms plus viral suppression — provides stronger protection than any single method alone.

Condoms are also the only prevention tool that also protects against other STIs — something PrEP and U=U don’t do. For comprehensive sexual health, condoms still play an important role alongside modern biomedical prevention, not instead of it.

Testing frequency depends on your level of ongoing risk:

The CDC recommends at least once a year for sexually active adults who are not in a mutually monogamous relationship with a tested partner. That’s a minimum baseline.

Every 3–6 months is recommended for people at higher risk: gay and bisexual men, people with multiple partners, people who inject drugs, or anyone who’s had a recent potential exposure. People on PrEP are tested every 3 months as part of standard PrEP monitoring.

After a possible exposure: Test at 45 days (with a 4th-generation antigen/antibody test) and again at 90 days if the first is negative. If it was a high-risk exposure within the last 72 hours, consider PEP first, then test on the schedule your provider recommends.

More frequent testing means earlier diagnosis, earlier treatment, and better outcomes. There’s no such thing as testing too often.

Combination prevention means using more than one prevention strategy at the same time to achieve the highest possible protection against HIV. The idea is simple: no single tool is perfect in real-world use, and layering methods compounds their effectiveness.

Examples of combination prevention in practice:
• Condoms + PrEP for people without HIV with multiple partners
• Viral suppression (U=U) + PrEP for the partner without HIV in a serodifferent couple
• PrEP + regular STI testing + harm reduction for people who inject drugs
• Condoms + regular testing + DoxyPEP for bacterial STI prevention

At the public-health level, combination prevention also means integrating biomedical tools with structural approaches: reducing stigma, addressing poverty and housing instability, expanding testing access, and decriminalizing drug use and sex work — all of which shape HIV risk at population level in ways no pill alone can fix.

Yes. People switch between PrEP options often, and providers plan for it.

Pills to injectable (Apretude / cabotegravir): your provider confirms you’re HIV-negative before switching (a routine step for any PrEP change). You get two loading doses one month apart, then one injection every two months. Some providers offer a short overlap where you keep taking pills up until your first injection to avoid any gap in protection.

Injectable to pills: take your first pill dose no later than 8 weeks after your last injection — the pharmacokinetic tail of cabotegravir keeps you protected until then. Ask your provider for a “PrEP-to-PrEP transition plan”; this is a well-known clinical scenario.

Reasons people switch: adherence (the injectable removes the “did I remember?” question), side effects, insurance coverage changes, travel, injection anxiety, or wanting more or less frequent contact with a clinic. Both forms are highly effective when used as prescribed. Switching is not failure.

Not soon, and probably not in the traditional sense. As of 2026, there is no HIV vaccine, and the major late-stage vaccine trials of the last decade — HVTN 702, Imbokodo, Mosaico — all failed to prevent infection and were stopped early.

Why HIV is so hard: the virus mutates faster than any known human pathogen, hides in reservoirs the immune system can’t reach, and specifically targets the immune cells (CD4 T cells) a vaccine would need to activate. Traditional vaccines train the immune system to recognize a stable target — HIV doesn’t offer one.

What’s actually promising in 2026:

• Broadly neutralizing antibodies (bnAbs) — lab-made antibodies that can block many HIV strains at once, being tested as periodic infusions or long-acting injections for prevention
• mRNA-based HIV vaccines — early-stage trials (IAVI, Moderna) testing whether the mRNA platform can teach the body to produce bnAbs on its own
• Long-acting PrEP — cabotegravir (2-monthly, approved) and lenacapavir (6-monthly, approved 2025) are effectively “chemical vaccines” — near-perfect prevention without daily pills. These are already here.

Bottom line: a sterile-immunity HIV vaccine may still be a decade or more away. But long-acting prevention already offers vaccine-like results.

Based on current evidence, GLP-1 medications appear safe alongside most ART regimens — no formal drug-drug interactions have been identified. That said, GLP-1s slow gastric emptying, which could theoretically affect absorption of some ARTs (particularly atazanavir and rilpivirine), and nausea from GLP-1s could affect ART absorption on especially difficult days.

Talk with your HIV provider before starting. No large HIV-specific trials exist yet, so they’ll be working from extrapolated evidence and clinical experience.

For people living with HIV, GLP-1s may offer added benefits beyond weight loss: reduction of metabolic syndrome, cardiovascular risk reduction, and possible anti-inflammatory effects — all relevant given HIV’s inflammatory effects on the body.

People living with HIV have a 50–100% higher risk of cardiovascular disease than peers without HIV — even on suppressive treatment. The main driver is chronic inflammation: HIV triggers persistent immune activation that quietly accelerates atherosclerosis even when viral load is undetectable.

The REPRIEVE trial showed pitavastatin (a statin) significantly reduced cardiovascular events in people living with HIV, even in those with low traditional risk scores. HIV is now classified as a “risk-enhancing condition” by the ACC/AHA — meaning the threshold for starting statin therapy should be lower for PLHIV than for the general population. If you’re over 40 and haven’t had this conversation, ask your provider whether a statin is right for you.

Yes, it’s extremely common — and yes, it does get better. Depression after an HIV diagnosis follows for very understandable reasons: grief, fear, stigma, and a sudden confrontation with mortality. That is real and deserves acknowledgment, not just management.

Depression in people living with HIV is also very treatable. SSRIs and SNRIs don’t significantly interact with most modern ART. Cognitive behavioral therapy (CBT) has strong evidence in PLHIV specifically. And peer support — connecting with others who understand from the inside — can help in ways clinical care alone cannot.

Treating depression directly improves HIV outcomes too: better adherence, better suppression, better overall health. You deserve care for your mental health as much as for your HIV — and both belong on the same care plan.

HIV accelerates some aspects of biological aging — a phenomenon researchers call “accelerated aging” or the “inflammaging” effect. People living with HIV may develop age-related conditions like cardiovascular disease, bone loss, neurocognitive changes, and frailty somewhat earlier than peers without HIV.

This doesn’t mean these outcomes are inevitable. It means proactive monitoring matters more. Annual HIV care should include: cardiovascular risk assessment, bone density screening for those over 50 (or earlier with risk factors), neurocognitive screening, cancer screening (particularly anal cancer for gay and bisexual men, cervical cancer for people with a cervix), kidney function, and mental health.

Lifestyle factors matter enormously: not smoking (the single biggest modifiable risk for PLHIV), exercise, diet, and sleep all have outsized impact on long-term outcomes. The HIV community also carries unique social dimensions of aging — including isolation, grief from epidemic losses, and long-term survivor syndrome — that deserve attention alongside physical health.

Sleep problems are significantly more common in people living with HIV than in the general population — affecting up to 70% of PLHIV in some studies. The causes are multiple and often overlapping:

Medication effects: Some ARTs, particularly efavirenz (older, less commonly used now), are strongly associated with vivid dreams and sleep disruption. Dolutegravir and bictegravir can also cause insomnia in some people, especially when taken at night. If your sleep disruption started when you began a new medication, mention it to your provider — switching to morning dosing or changing regimens can help.

Anxiety and depression: Extremely common after diagnosis and across the HIV experience, and both strongly affect sleep. Treating the underlying mental health condition is often the most effective approach.

HIV-related inflammation: Chronic immune activation can disrupt sleep architecture even with viral suppression.

Tell your HIV provider about sleep problems — they’re treatable, and they affect everything else including adherence and quality of life. You don’t have to just live with it.

No specific “HIV diet” is required — but nutrition matters somewhat more for people living with HIV than for the general population, because HIV-related inflammation and some ARTs can affect metabolism, body composition, and nutrient absorption.

General principles that apply well to PLHIV:
• Anti-inflammatory eating patterns (Mediterranean-style) benefit cardiovascular health, especially relevant given HIV’s cardiovascular effects
• Adequate protein supports muscle maintenance, particularly important as you age
• Calcium and vitamin D for bone health, given HIV’s effects on bone density
• Limiting alcohol protects liver function and supports ART efficacy

Food-drug interactions are worth checking for your specific regimen. Some ARTs should be taken with food, others on an empty stomach. Grapefruit and certain supplements can affect drug metabolism. Your HIV pharmacist is an excellent (and often underused) resource for regimen-specific guidance.

Not only safe — it’s one of the single best things you can do for your HIV health specifically. Studies show regular exercise in people living with HIV:
• Reduces inflammatory markers that drive cardiovascular risk
• Improves CD4 counts in some studies
• Reduces depression and anxiety
• Improves sleep quality
• Supports bone density
• Reduces fat redistribution effects associated with some older ARTs

For PLHIV on effective ART, there are no HIV-specific contraindications to exercise. If you’re starting from a low baseline, even 20–30 minutes of walking a few times a week produces meaningful benefits. Consistency beats intensity, and something is always better than nothing.

What you’re describing is real, common among long-term survivors, and doesn’t get talked about nearly enough.

The grief of having survived an epidemic that took so many people around you, the years of disclosure decisions and secrecy, the internalized shame that can accumulate quietly over decades — these things don’t just resolve because treatment improved. They need to be witnessed, not just managed.

Long-term survivor programs, community organizations, and therapists with HIV experience can hold this in ways routine clinical care cannot. Groups like The Reunion Project, Survive & Thrive, and regional long-term survivor coalitions exist specifically for this.

You are not alone in feeling alone. And that’s worth saying directly.

Yes — HIV itself and some ART medications are associated with lower bone mineral density compared to peers without HIV. People living with HIV have a somewhat higher risk of osteopenia, osteoporosis, and fractures than the general population of the same age.

The causes are multiple: HIV-driven inflammation directly affects bone metabolism, older ART regimens (particularly TDF-containing ones) affected bone density more than modern TAF-containing drugs, and PLHIV have higher rates of vitamin D deficiency, which is important for bone health.

What to do: Bone density screening (DEXA scan) is recommended for PLHIV at age 50 (earlier if other risk factors exist). Calcium and vitamin D supplementation is appropriate for many. Weight-bearing exercise helps maintain bone density. Smoking cessation matters — smoking significantly worsens bone density loss on top of everything else.

If you’re over 50 or have been on ART for many years, ask your HIV provider whether a bone density scan is warranted for you.

Smoking is the single most important modifiable risk factor for long-term health in people living with HIV — and it matters even more than it does for the general population, because HIV already elevates cardiovascular, pulmonary, and cancer risk through chronic inflammation.

Research has found that PLHIV who smoke lose more life-years to tobacco than to HIV itself. Smoking dramatically compounds the already-elevated cardiovascular risk. It raises lung cancer risk (already higher in PLHIV). It affects immune function and ART efficacy. It worsens bone density loss. And it amplifies the inflammatory burden that HIV already creates.

Quitting is the single most evidence-based thing a smoking person living with HIV can do for long-term health. If you smoke, talk to your HIV provider about cessation support — including medications like varenicline (Chantix) that are safe with most ART regimens and significantly improve quit rates. It’s rarely a one-attempt thing, and there’s no shame in trying more than once.

Many people living with HIV use cannabis for pain, nausea, appetite, sleep, or relaxation. Cannabis does not have a major interaction with most modern HIV regimens, but the answer is not identical for every medication, dose, or form of cannabis.

Tell your HIV provider or pharmacist what you use — including edibles, CBD products, and medical marijuana — so they can check for interactions and help you weigh side effects such as dizziness, anxiety, memory changes, or smoke-related lung irritation. That conversation is about safer care, not judgment.

If cannabis is getting in the way of taking medication, sleep, work, or how you feel emotionally, bring that up too. Your care team can help you find an approach that supports your goals.

Some HIV medications can affect kidney function, but modern HIV care is built to catch problems early. HIV itself, high blood pressure, diabetes, aging, and certain medications can also affect the kidneys, so it is important to look at the whole picture rather than assume one cause.

Your provider will usually monitor kidney function with blood tests and, when appropriate, urine testing. Tenofovir disoproxil fumarate (TDF) deserves particular attention for people with kidney risk factors; another form, tenofovir alafenamide (TAF), may be easier on the kidneys for some people.

Do not stop ART because of a lab result or a worry about side effects. Ask what your numbers mean, whether any other medicines or supplements matter, and what follow-up is right for you.

Yes. People living with HIV are eligible for — and strongly encouraged to get — several vaccines beyond what’s recommended for the general population. HIV weakens some immune responses, so both extra protection and, in some cases, extra doses are needed.

Routinely recommended for people living with HIV:

• Pneumococcal (PCV20 or PCV15+PPSV23) — pneumonia is a leading cause of hospitalization for PLHIV
• Hepatitis A and B — HAV series once; HBV requires higher-dose or double-dose schedule with titers checked afterward
• HPV vaccine (Gardasil-9) — recommended through age 45 for PLHIV (versus 26 in the general population), because HPV-driven anal, cervical, and oropharyngeal cancers are much more common
• Influenza annually — inactivated only; no live nasal spray
• COVID-19 — updated formulation each fall
• Mpox (JYNNEOS) — 2-dose series, especially for MSM, trans people, and anyone at ongoing exposure risk
• Shingles (Shingrix) — recommended starting at age 19 for PLHIV (versus 50 for the general population)
• RSV — recommended for adults 60+ and PLHIV with additional risk factors
• Tdap and Td boosters — standard schedule

Avoid live vaccines if your CD4 is below 200: MMR, varicella, yellow fever, live typhoid. Once your CD4 rebounds above 200 and stays there for 6+ months, most live vaccines become safe. Talk with your HIV provider before international travel.

There’s no single right answer — disclosure timing is personal and situational. What most people living with HIV land on: early enough in a connection that it feels honest, but not so early that it becomes the entire first conversation.

A few things that help: knowing your facts (especially U=U), choosing a calm private moment rather than a charged one, and having a mental script that feels natural to you. Practice actually helps — saying the words out loud to yourself, or to a friend, takes some of the weight off.

Some people disclose via dating apps before meeting — it filters for acceptance and avoids the in-person anxiety. Others prefer to establish connection first. Both are valid.

Rejection happens. When it does, it reflects the other person’s knowledge and fears — not your worth. And the right people stay.

Absolutely. Millions of people are in “serodifferent” or “mixed-status” couples — one partner living with HIV, one without HIV — and live full, healthy, loving lives together.

With U=U, an partner living with HIV who is virally suppressed on treatment poses zero risk of sexual transmission to their negative partner. The PARTNER and PARTNER 2 studies confirmed this across thousands of couples and tens of thousands of acts of condomless sex — zero linked transmissions.

Many serodifferent couples also use additional prevention layers (PrEP for the negative partner, condoms) for added peace of mind, or because one partner isn’t yet suppressed. These choices are personal, not required.

Communication, honesty, and a shared understanding of the science tend to be the foundations of serodifferent relationships that thrive.

Both terms describe a couple where one partner is living with HIV and the other is without HIV. “Serodiscordant” is the older clinical term — “discordant” meaning different. “Serodifferent” is the newer, increasingly preferred term because it’s neutral rather than framing the difference as a problem.

You may also hear “mixed-status couple” — same meaning, more conversational.

These relationships are common, healthy, and with modern tools — particularly U=U and PrEP — can involve no meaningful HIV transmission risk. Many people living with HIV are in long-term serodifferent relationships with partner without HIVs.

Yes — fully and without apology. HIV does not define what you deserve sexually or romantically.

With modern treatment and U=U, people living with HIV who are undetectable have sex lives that are medically indistinguishable in risk from people without HIV. The conversation has shifted from “is it safe?” to “what do you want?”

What does require navigating: disclosure decisions, the emotional weight of stigma, and occasional encounters with people whose knowledge of HIV is stuck in 1992. These are real — but they are not reasons to deprive yourself of connection and intimacy.

Many PLHIV find that their diagnosis actually deepens their capacity for honest, authentic connection. Not despite HIV — sometimes because of what it demanded of them.

Extremely common, and rarely talked about honestly enough. HIV stigma — both from the outside world and internalized — runs deep. Many people living with HIV describe feeling “damaged,” less desirable, or unworthy of intimacy after diagnosis. These feelings are a product of stigma, not a reflection of reality.

The medical facts: you can have a full, healthy, satisfying sex life and intimate relationships with HIV. U=U means you are not a danger to others when undetectable. Your worth as a person and partner is not diminished by your diagnosis.

Working through internalized stigma often benefits from therapy — particularly with a therapist who has experience with HIV or chronic illness — and from peer community. Hearing from other PLHIV who have navigated this is often more powerful than clinical information alone.

Yes. Several platforms exist specifically for people living with HIV or HIV-aware singles:

Poz Personals (poz.com/personals) — one of the longest-running HIV-specific communities.
Hzone — dating app for people living with HIV and their supporters.
PositiveSingles — broader STI-aware dating community that includes living with HIV members.

Mainstream apps (Grindr, Scruff, Hinge, Tinder) also have status disclosure features to varying degrees. Grindr allows users to list HIV status and last test date. Many PLHIV use mainstream apps successfully, handling disclosure in whatever way feels right to them.

There’s no single right platform. The most important thing is finding a space where you feel safe being honest.

Chemsex refers to the use of specific substances — most commonly crystal meth (methamphetamine), GHB/GBL, and mephedrone — in the context of sexual activity, particularly (but not exclusively) among gay and bisexual men.

The HIV-related risks include: reduced inhibition leading to missed doses or skipped prevention measures, injection drug use (needle sharing) in some chemsex contexts, and the cognitive effects of meth specifically accelerating neurocognitive changes in people living with HIV.

If chemsex is part of your life, harm reduction approaches are available without judgment: maintaining PrEP or ART adherence even during use, having naloxone available (GHB/GBL overdose can be life-threatening), using new equipment for any injection, and having a trusted person who knows where you are.

Many sexual health and HIV clinics now have chemsex-specific support programs. You don’t have to navigate this alone, and you don’t have to be ready to stop to ask for help.

There is no script that works for every family — but some things tend to help:

Come prepared with facts. Many family members’ initial fear is rooted in outdated information — “Is this a death sentence?” Having clear, calm answers ready (treatment works, people live long healthy lives, undetectable means untransmittable) can defuse panic quickly.

Choose your moment carefully. A private, low-stress setting — not during an argument, not at a family gathering, not over text.

Don’t disclose to everyone at once if you can avoid it. Start with the person most likely to be supportive. Let yourself have at least one person in your corner before navigating harder conversations.

Give them time. The people who love you may need time to process. An initial difficult reaction doesn’t always predict the long-term response.

Some families surprise you with love. Some don’t show up the way you need. Both are real outcomes — and support is available regardless of what happens with family.

Faith and HIV intersect in complex ways. For many people living with HIV, faith community is a source of profound support, meaning, and belonging. For others — particularly in communities where HIV has been framed as moral punishment — religious stigma adds a painful layer to an already difficult experience.

Many faith traditions have moved toward more affirming, compassionate responses to HIV over the decades. HIV-supportive congregations and faith-based HIV organizations exist across Florida and nationally.

You don’t have to choose between your faith and your full self. If your current faith community is a source of shame rather than support, there are others — including many that actively welcome and minister to PLHIV.

You also have no obligation to disclose your status to your religious community.

Yes. Transgender women — particularly Black and Latina transgender women — face among the highest HIV rates of any population in the U.S. Estimates suggest HIV prevalence among transgender women is 14–49 times higher than in the general adult population.

These elevated rates reflect structural vulnerabilities, not individual behavior: housing instability, discrimination in employment and healthcare, criminalization of sex work, violence, and systemic exclusion from healthcare systems that were not designed with transgender people in mind.

Important clinical notes: gender-affirming hormone therapy and ART can interact — your HIV provider needs to know about your hormone regimen. Some older enzyme-inducing ARTs can affect hormone levels. Modern integrase inhibitor regimens (Biktarvy, Dovato, Triumeq) have fewer interactions, but this should always be reviewed with your provider.

HIV-specific resources for transgender women include: Trans Lifeline, National Center for Transgender Equality, and HIV-specialized providers with transgender health expertise. Use our Florida care locator to find affirming care providers.

Start by asking what support they want. For one person, that may mean a ride to an appointment or help with a pharmacy refill; for another, it may simply mean being someone who listens without making HIV the center of every conversation.

With their permission, you can help organize appointments, medication refills, questions for the care team, and practical needs such as food, transportation, or insurance paperwork. A signed release can let clinicians speak with you directly, but privacy still belongs to the person receiving care.

Caregiving can be meaningful and exhausting at the same time. Ask a case manager about support services, take breaks, and make room for your own health too.

The answer depends on where you live, whether you’re on treatment, and what protection is used — and it’s more nuanced than “yes” or “no.”

The legal reality in Florida: Florida’s HIV criminalization law (Florida Statute 384.24) currently requires disclosure before “sexual intercourse” for people who know they have HIV, regardless of viral load, condom use, or actual transmission risk. Violation is a third-degree felony. This applies to all partners — one-time, anonymous, ongoing.

Reform is happening but hasn’t reached Florida yet. Colorado, California, Illinois, Michigan, Nevada, New Jersey, North Carolina, Virginia, and Washington have modernized their HIV laws — most now require actual intent to transmit and recognize undetectable status as a defense. Florida has not.

Practical harm reduction if you’re not going to disclose: be undetectable and stay that way. Use condoms — they’re a defense in many prosecutions even under old laws. Understand that being undetectable is not currently a defense in Florida, even though the actual transmission risk is zero.

Ethical harm reduction: many people living with HIV feel a moral responsibility to disclose regardless of what the law requires or the medical risk indicates. Others don’t, especially with anonymous partners and when U=U applies. There is no single right answer, and this site does not tell you how to feel about it.

Yes. Florida Statute § 384.24 creates criminal liability for people living with HIV who engage in sexual activity without disclosing their status. It’s a first-degree misdemeanor for sexual intercourse without disclosure, rising to a third-degree felony in cases involving prostitution.

Florida’s law does not require actual transmission, does not require intent to transmit, and does not formally recognize viral suppression (U=U) as a complete defense — even though the science shows undetectable people cannot transmit sexually.

Florida remains among the most aggressive states for HIV criminalization. Advocates have pushed for reform to align the law with current science, without success so far. If you are facing a legal situation, contact an HIV legal advocacy organization immediately — before making any statements to police or investigators.

No. HIV is protected as a disability under the Americans with Disabilities Act (ADA). You are not required to disclose your status to an employer. They cannot ask about HIV status during hiring, fire or demote you because of HIV, or require HIV testing as a condition of employment (with very narrow safety-sensitive exceptions).

If you experience HIV-related workplace discrimination, file a complaint with the EEOC. In Florida, Southern Legal Counsel and Disability Rights Florida handle HIV-related discrimination cases and can help you understand your options.

In the U.S.: The HIV immigration and travel ban was lifted in 2010. People living with HIV can obtain green cards and most visas without being disqualified based on HIV status alone.

Internationally: Some countries still have HIV-related entry restrictions or long-stay bans. Check hivtravel.org for country-by-country information before traveling, especially for work visas, study abroad, or long-term stays.

Immigration law is complex — consult an immigration attorney with HIV experience for your specific situation.

No. Housing discrimination based on HIV status is illegal under federal law. The Fair Housing Act prohibits discrimination in the sale, rental, and financing of housing based on disability — and HIV is protected as a disability.

This means a landlord cannot: refuse to rent to you because of HIV, evict you because of HIV, or apply different terms or conditions to your tenancy because of HIV.

You are not required to disclose your HIV status to a landlord. If you experience housing discrimination related to HIV, you can file a complaint with the U.S. Department of Housing and Urban Development (HUD) or contact a local fair housing organization.

Ryan White also funds housing assistance programs (HOPWA — Housing Opportunities for Persons With AIDS) for people living with HIV who are experiencing housing instability.

People living with HIV involved in sex work face compounding legal vulnerabilities in Florida. Florida’s HIV criminalization statute increases the charge to a third-degree felony when the person is engaging in prostitution — regardless of viral load, condom use, or actual transmission risk.

This creates a situation where people living with HIV in sex work face felony-level criminal exposure that their peers without HIV do not face for the same activity. Advocates argue this is both scientifically unfounded and unjust — particularly given U=U.

If you are involved in sex work and navigating legal or safety concerns related to HIV, organizations like SWOP (Sex Workers Outreach Project) and local HIV legal advocacy organizations can provide support and information without judgment.

No — legally. The Americans with Disabilities Act (ADA) and Section 504 of the Rehabilitation Act prohibit healthcare providers from discriminating against people living with HIV. A provider cannot refuse to treat you, charge you more, or provide a lower standard of care because of your HIV status.

The CDC has long maintained that standard infection control precautions (gloves, proper instrument sterilization) are sufficient for treating PLHIV — and these same precautions are used for all patients regardless of HIV status.

In practice, healthcare discrimination does still occur — particularly in dental care. If you experience it, you can file a complaint with the Office for Civil Rights at the U.S. Department of Health and Human Services, or contact a local HIV legal advocacy organization.

Yes — slowly. HIV criminalization reform has been an active advocacy priority for over a decade, and a number of states have modernized their laws.

States that have significantly reformed HIV criminalization laws include California (2017), Iowa (2014), Illinois (2021), Michigan (2023), and most recently Louisiana (2025), among others. These reforms typically include: requiring proof of intent to transmit, recognizing viral suppression and condom use as defenses, and reducing or eliminating criminal charges where no actual transmission risk existed.

Florida has not modernized its HIV criminalization laws, which remain among the most punitive in the country and do not reflect current science.

National organizations working on HIV criminalization reform include The Elizabeth Taylor AIDS Foundation (through its “HIV Is Not A Crime” campaign), the Sero Project, and Lambda Legal.

Life insurance: Historically, people living with HIV were denied life insurance outright. This is changing. As HIV prognosis has dramatically improved, some insurers now offer policies to PLHIV who are virally suppressed and meet other health criteria. The market is evolving — working with a broker who has experience with high-risk life insurance is the best approach.

Disability benefits: HIV-related disability can qualify for Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) if it substantially limits your ability to work. An AIDS diagnosis, very low CD4 counts, or HIV-related complications can support a disability claim. Many people apply with the help of a social worker or disability advocacy organization — the paperwork is significant.

Ryan White programs and AIDS service organizations often have benefits counselors who can help navigate SSDI, SSI, Medicare, and Medicaid enrollment — use our care locator to find one.

No. Children living with HIV have the right to attend school under federal law. The Individuals with Disabilities Education Act (IDEA), Section 504 of the Rehabilitation Act, and the Americans with Disabilities Act all prohibit schools from excluding children based on HIV status.

The CDC, the American Academy of Pediatrics, and every major medical authority have long held that children living with HIV pose no risk to classmates or teachers through normal school activities. There is no medical justification for exclusion.

You are not required to disclose a child’s HIV status to the school. A family may choose to disclose to enable certain accommodations, but this should be a voluntary decision made with full understanding of the school’s confidentiality practices — because unfortunately, disclosure can sometimes trigger informal discrimination despite legal protections.

You are not required to announce your status at the front desk, and dental offices are required to use standard infection-control precautions with every patient. They cannot refuse to treat you simply because you are living with HIV.

Still, sharing relevant health information with the clinician can help them provide safer, better care. Your HIV medications, CD4 count or viral load when relevant, dry mouth, infections, and possible drug interactions can all affect a dental plan. You can ask how your information will be protected and speak privately with the dentist rather than discuss it in a waiting room.

If a dental office treats you differently because of HIV, document what happened and seek legal or advocacy support.

Possibly. The HOPE Act opened the door to HIV-to-HIV organ donation and transplantation in the United States. A person living with HIV may be able to donate a kidney or liver to another person living with HIV, and people living with HIV may also be candidates to receive those organs.

Eligibility is decided case by case by the transplant team. It depends on factors such as overall health, organ function, viral suppression, other infections, and the rules at the transplant center. The process is not a promise of eligibility, but HIV status alone should not end the conversation.

If donation or transplant is on your mind, ask your HIV provider for a referral to a transplant program with HIV experience.

Yes, in a shrinking but still significant number of places. As of 2026, roughly 17 countries still restrict entry, stay, or residency for people living with HIV. This is down from over 60 countries a decade ago, but the remaining restrictions matter if you’re planning to travel, work abroad, or emigrate.

Countries with the strictest restrictions: Russia, Brunei, United Arab Emirates, Kuwait, Qatar, Oman, Saudi Arabia, Yemen, Solomon Islands, Papua New Guinea, Turks & Caicos, Iraq, Egypt, Belarus, Malaysia, and Singapore (long-stay only).

Countries that recently lifted restrictions: US (2010), China (2010), South Korea (2010), Namibia (2015), Uzbekistan (2020), Bahrain, Mongolia — this list is growing.

What travelers should know:

• Short tourist visits are usually fine even to restricted countries — HIV status is typically only checked for stays over 90 days, work visas, or residency applications
• Never carry HIV medications in checked luggage; carry them in original prescription bottles with a doctor’s letter
• Bring a full supply plus extra — some restrictive countries will confiscate HIV medications at the border
• Check current status at the UNAIDS HIV Travel Restrictions database or hivtravel.org

The Ryan White HIV/AIDS Program is the federal safety net for HIV care — the largest federally funded program built specifically for people living with HIV. It funds HIV care for people who are uninsured, underinsured, or otherwise can’t afford care.

What it can cover: Medical care, HIV medications (through ADAP), case management, mental health, substance use services, oral health, transportation, housing assistance, and more — the exact mix depends on your local Ryan White program.

Ryan White is not insurance — it’s the payer of last resort that fills the gaps around whatever coverage you do or don’t have. Eligibility is based on HIV status, income (generally up to 400% of the federal poverty level), and insurance status. Use our Florida care locator to find Ryan White-funded providers near you.

ADAP (AIDS Drug Assistance Program) is the Ryan White component that pays for HIV medications for people living with HIV who can’t afford them. Each state runs its own ADAP with a mix of federal and state funding, so eligibility rules and drug formularies vary from state to state.

In Florida, ADAP is administered through the Florida Department of Health. You don’t apply on your own — you enroll through a Ryan White-funded HIV clinic or AIDS service organization, and a case manager walks you through the paperwork, verifies income and insurance status, and gets you started on medication as quickly as possible.

The fastest path in: use our Florida care locator to find a Ryan White provider near you and ask to be connected to a case manager. Enrollment is confidential and free.

Almost every person living with HIV in the U.S. can access their medication at low or no cost. The path in usually combines two or three of these:
• Ryan White / ADAP — free HIV medications for people who qualify by income
• Manufacturer Patient Assistance Programs — Gilead Advancing Access, ViiVConnect, and Janssen all offer free medication for uninsured people below income thresholds
• Copay assistance cards — for people with private insurance; often reduce out-of-pocket cost to $0
• Medicaid — if you’re income-eligible, covers HIV drugs with minimal copays
• ACA Marketplace — with subsidies, plans can be very affordable and cover HIV drugs

A Ryan White case manager can put the pieces together for you — that is literally their job, and they do it every day. Use our care locator to find one near you.

Yes — Florida Medicaid covers HIV medications and HIV-related medical care for people who qualify. But Florida is one of the states that has not expanded Medicaid under the ACA, so the income cutoff is much lower here than in expansion states, and the coverage gap is real.

In Florida, Medicaid for adults is generally limited to very low-income parents, pregnant people, people with disabilities, and those who qualify for SSI. Many low-income adults without children do not qualify for Florida Medicaid — even if they are living with HIV. This is one of the biggest reasons Ryan White matters so much in this state.

If you fall into the coverage gap, Ryan White and ADAP are the primary pathways to care and medication. A Ryan White case manager can look at your full picture and stitch together the best combination of coverage for your situation.

An HIV case manager is one of the most valuable resources available to people living with HIV — and one of the most underused. Case managers at Ryan White-funded HIV clinics and AIDS service organizations help clients navigate the entire system of HIV-related services, and their help is free.

What they can help with:
• Enrolling in Ryan White, ADAP, Medicaid, or ACA insurance
• Applying for manufacturer patient assistance programs for free medication
• Navigating housing assistance (HOPWA)
• Connecting to mental health, substance use, or peer support services
• Transportation to medical appointments
• Food assistance programs
• Helping you understand your rights and benefits

If you don’t have a case manager, ask for one at your HIV clinic. Use our Florida care locator to find Ryan White-funded providers that include case management.

Worries about HIV coverage come up for a lot of reasons — a job change, an insurance change, a move between states, or a headline about program funding. The single most protective thing you can do is stay in stable care with a Ryan White-funded clinic and know your backup options before you actually need them.

What you can do now:
• Stay in stable care — established patients at Ryan White clinics generally have the smoothest experience if anything about your coverage changes
• Know your backup coverage options — ACA Marketplace plans, manufacturer patient assistance programs (Gilead, ViiV, Janssen), and Medicaid are all safety nets that exist for exactly this
• Work with a case manager — a Ryan White case manager can map out every program you qualify for and set up a fallback before you ever need it
• Stay connected to community — local and national HIV organizations track policy changes and mobilize when it matters, and being on their lists means you hear about changes early

Use our Florida care locator to find a Ryan White provider near you.

Most private insurance and Medicaid plans in Florida cover PrEP, though prior authorization is sometimes required for injectable options like Apretude or Yeztugo. Under the ACA, most insurance plans are required to cover oral PrEP with no cost-sharing at all — no copay, no deductible.

Florida ADAP can also cover PrEP for income-eligible Floridians without adequate coverage. The federal Ready, Set, PrEP program provides free Truvada or Descovy to uninsured Americans who qualify.

Gilead Advancing Access and ViiVConnect offer free or reduced-cost PrEP — including the injectable options — for people who are uninsured. Your PrEP provider or Ryan White case manager can help you find the right combination of programs.

Dental care is a notorious gap in HIV coverage. Many insurance plans, including Florida Medicaid, have very limited adult dental benefits — and dental problems are common for people living with HIV due to dry mouth from some medications, immune effects, and the ordinary stress that comes with a chronic condition.

Options for affordable dental care as a person living with HIV:
• Ryan White Part A and B programs in many Florida regions include oral health services — ask your case manager whether your area covers dental
• Federally Qualified Health Centers (FQHCs) — many have on-site dental clinics that charge on a sliding-fee scale based on income. Find one at findahealthcenter.hrsa.gov
• Dental school clinics — Florida has several dental schools (UF, Nova Southeastern, Lake Erie) with clinics that provide care at significantly reduced cost, done by supervised students
• Community health fairs and free dental days run by local organizations, especially in urban areas

Use our Florida care locator to find HIV-friendly providers, and ask specifically about oral health services when you call.

The Veterans Health Administration is one of the country’s largest HIV care systems. Start by enrolling in VA health care, then ask your VA primary-care team for an HIV or infectious-disease referral. If you already take ART, bring your medication list and do not wait until your supply is almost gone.

Your VA team can help coordinate HIV visits, labs, pharmacy access, mental-health care, and other services. If specialty care is far away, ask whether telehealth, a nearby VA clinic, or VA Community Care may be available for your situation.

Benefits, copays, and eligibility can be personal and sometimes complicated. A VA social worker, benefits counselor, or HIV case manager can help you understand the options you have earned.

Start with the difference between the programs: SSDI is tied to work history, while SSI is needs-based and has strict income and resource rules. An HIV diagnosis alone does not automatically qualify someone for disability benefits; eligibility depends on how a condition affects work and daily life.

Before taking a job, changing hours, accepting a payment, or building savings, get benefits-specific guidance. Earnings can affect SSI, SSDI, Medicaid, Medicare, food assistance, and Ryan White eligibility in different ways. Work incentives and tools such as ABLE accounts may help some people save or work without losing support immediately.

A benefits counselor, social worker, or legal-aid advocate can help you make a plan that fits your income, health coverage, and goals. You do not have to do that math alone.

Turning 65 can mean a Medicare transition, a chance to review your care team, and a good time to build a fuller long-term health plan. Do not assume that Medicare automatically covers every medication, dental need, or support service in the same way your current coverage does.

Before your enrollment window closes, ask a benefits counselor or case manager to compare Medicare options, prescription coverage, Medicaid or Medicare Savings Program eligibility, and how Ryan White services may fill gaps. Bring your complete medication list so a plan’s formulary and pharmacy rules can be checked.

It is also a good time to review heart, bone, kidney, cancer-screening, cognitive, and mental-health care with your provider. Aging with HIV is not one-size-fits-all; a plan that reflects your history and priorities matters.

The 340B Drug Pricing Program is a federal law that lets certain safety-net providers — including Ryan White HIV clinics and Federally Qualified Health Centers — buy prescription drugs at deeply discounted prices, then bill insurance or Medicaid at closer-to-market rates. The clinic keeps the difference and reinvests it in patient care.

How it directly helps you:

• Ryan White clinics use 340B revenue to fund the wraparound services that traditional Medicaid or private insurance don’t cover — case management, transportation vouchers, mental health, dental, food support, emergency financial help
• Without 340B, many Ryan White clinics would close or dramatically reduce services
• Roughly 60% of all people living with HIV in the US receive care from a Ryan White-funded provider, and 340B is one of the funding pillars that keeps those clinics running

Why it’s politically contested in 2026: pharmaceutical companies argue 340B has expanded beyond its original purpose. Multiple lawsuits, HHS rule changes, and manufacturer restrictions on contract pharmacies threaten the program. Advocates including AIDS United, NASTAD, and Ryan White grantees warn that weakening 340B would collapse HIV safety-net care.

What this means for you: if the Ryan White clinic you use offers services beyond just your HIV meds — free dental, food pantry, transportation, case management — 340B is likely paying for those. Cuts to the program would hit hardest in places like Florida that don’t have Medicaid expansion.

Sometimes, but it’s rarely your best option. GoodRx and similar discount programs can reduce HIV medication prices — but for most people with HIV, better assistance already exists that gets you to $0 out-of-pocket.

When GoodRx might help:

• You’re between insurance plans and need an emergency 30-day supply
• You’re waiting for ADAP or Ryan White enrollment to complete
• You’re on a generic older regimen where GoodRx pricing beats other options
• You’re picking up a related medication (like a statin, antidepressant, or ED med) that your HIV benefits don’t cover

Why it’s usually not the answer: GoodRx coupons don’t apply to Medicare, Medicaid, or Ryan White prescriptions in most cases. The “discounted” price on new HIV medications is still $2,000–$4,000/month. Using GoodRx bypasses your insurance, so it doesn’t count toward your deductible or out-of-pocket maximum.

What to use instead: ADAP (free HIV meds in Florida if you qualify), manufacturer patient assistance programs (Gilead Advancing Access, ViiV Patient Assistance, Merck Patient Assistance), Ryan White Part B / ADAP wrap for people with insurance who can’t afford copays, and 340B pharmacies at Ryan White clinics. Talk to your case manager first — coupons are a last resort, not a first option.

Being uninsured does not shut you out of HIV care in Florida. Several pathways exist:
• Ryan White-funded HIV clinics — comprehensive care on a sliding-scale or free basis. Present in every major metro area and many rural counties.
• FQHCs (federally qualified health centers) — sliding-fee scale regardless of insurance status. Many now offer HIV specialty services. Find one at findahealthcenter.hrsa.gov.
• Florida ADAP — covers HIV medications for income-eligible Floridians.
• County health departments — HIV clinics or warm referrals in most counties.

Use our Florida HIV Services Locator (searchable by ZIP, city, region, and service type) to find care near you. Or call Florida DOH HIV/AIDS: 1-800-352-2437.

First: breathe. HIV today is a manageable chronic condition, and Florida has a real support system built around exactly this moment. Here’s the order that works:
Step 1 — Get into HIV care. Your testing site can often refer you directly. If not, use our Florida care locator.
Step 2 — Ask for a Ryan White case manager. They handle insurance, medication access, housing referrals — the whole tangle — and their help is free.
Step 3 — Understand Florida ADAP. If you’re uninsured, ADAP can cover your HIV medications. Your case manager enrolls you.
Step 4 — Connect with community. Florida has active AIDS service organizations in Tampa, Miami, Orlando, Jacksonville, Fort Lauderdale, and beyond — and peer support makes a real difference in the first year.

Rural HIV care in Florida has genuinely gotten better in the last few years. A few options worth knowing about:
• Telehealth — many Florida HIV providers now offer telehealth for established patients. Local lab work plus remote review keeps you on stable care without long drives.
• Rural FQHCs — federally qualified health centers exist in many rural Florida counties. Search findahealthcenter.hrsa.gov.
• County health departments — reach into rural areas and can provide referrals or, in some counties, basic HIV care.
• Long-acting injectables — Cabenuva every 2 months for treatment, or Apretude every 2 months / Yeztugo every 6 months for PrEP, dramatically reduce how often you need to be in a clinic.

Florida consistently ranks among the top three states for new HIV diagnoses in the U.S., with roughly 4,000 to 5,000 new diagnoses reported each year in recent years (see AIDSVu’s Florida profile for the current numbers). Miami-Dade County alone regularly ranks as one of the highest-burden counties in the entire country.

The epidemic in Florida is concentrated but widespread: South Florida (Miami-Dade, Broward, Palm Beach) carries the heaviest burden, but Tampa Bay, Orlando, Jacksonville, and rural Florida all have significant and underserved populations of people living with HIV.

Florida’s epidemic disproportionately affects Black and Latino communities, gay and bisexual men, and people in low-income urban and rural areas. These disparities reflect structural inequities in access to testing, PrEP, and care — not differences in individual behavior.

PrEP is available from a wide range of providers across Florida — not just HIV specialists. Primary care providers, Planned Parenthood locations, county health departments, and FQHCs can all prescribe PrEP.

Cost assistance options in Florida include: Florida ADAP for income-eligible residents, the federal Ready, Set, PrEP program for uninsured people, and manufacturer patient assistance programs from Gilead and ViiV.

Use our Florida HIV Services Locator — filter by PrEP services — to find providers near you. Telehealth PrEP has expanded significantly in Florida, so in many cases you can start PrEP without a traditional clinic visit.

Black Floridians carry a disproportionate share of new HIV diagnoses — a disparity driven by structural factors, not individual behavior.

The structural drivers include: less access to regular healthcare and HIV testing; lower rates of PrEP uptake because of cost, awareness, and provider availability; higher rates of poverty and housing instability that compound health risk; medical distrust rooted in documented historical mistreatment of Black patients by the healthcare system; and HIV stigma that is particularly intense in some communities and discourages testing and disclosure.

The disparity exists not because Black Floridians engage in riskier behavior, but because they face greater barriers to the tools that prevent and manage HIV — barriers that are the product of systemic inequality.

Closing this gap requires both targeted community outreach and structural change: expanded access, culturally competent care, and removing the economic and social barriers that make prevention and treatment harder to reach.

Yes — many Florida HIV service providers offer Spanish-language services, particularly in South Florida, Tampa, and Orlando where Latino populations are large. A lot of Ryan White-funded clinics have bilingual staff and Spanish-language patient materials as a standard part of care.

Latino Floridians are disproportionately affected by HIV, and language access is a core piece of equitable care. If English is not your primary language, you have the right to a qualified interpreter at any federally funded healthcare facility — that’s federal law, not a favor.

When searching our Florida care locator, look for organizations with explicit Spanish-language services listed. Community health centers (FQHCs) in high-Latino-population areas are often the most reliably bilingual providers.

This page is also available in Spanish — use the ES button at the top of this page.

Free HIV testing is widely available in Florida:

• County health departments — most Florida counties offer free confidential HIV testing
• Planned Parenthood — free or low-cost testing at locations across Florida
• Community health centers (FQHCs) — sliding-scale testing with no one turned away for inability to pay
• HIV clinics and AIDS service organizations — many offer free walk-in testing
• gettested.cdc.gov — CDC’s testing locator with ZIP-code search
• Our locator — Florida HIV Services Locator, searchable by ZIP code

Testing in Florida can be confidential (your name is attached to results, which are kept private) or anonymous (no name attached at all), depending on the location and test type. Ask about anonymous options when you call or visit.

Florida’s legal and operational landscape around syringe service programs (SSPs) is complex and inconsistent. Florida law has historically restricted possession of syringes without a prescription, though the state passed the Infectious Disease Elimination Act (IDEA) in 2019 authorizing counties to opt in to running SSPs.

Some Florida counties have authorized or operated SSPs, while others have not. Miami-Dade (via IDEA Exchange) and several other urban counties have had active programs. Availability and legal status varies significantly by county and continues to evolve.

For current SSP availability in Florida, contact a local harm reduction organization or use our Florida care locator — filter for harm reduction services. NEXT Distro also operates a mail-based naloxone and harm reduction program that reaches Floridians statewide.

Yes. Young people (ages 13–24) represent a disproportionate share of new HIV diagnoses in Florida, and youth-specific services exist across the state.

Several Florida Ryan White programs have youth-specific clinics or services designed around the realities of being young and living with HIV — including wraparound support for housing, education, and mental health alongside medical care. Some programs partner with schools, youth centers, or LGBTQ+ organizations.

Young people in Florida can access HIV testing, PrEP, and STI services confidentially without parental consent under the state’s minor consent laws. That protection matters for youth who aren’t ready to disclose to parents.

Use our Florida care locator to find youth-specific HIV programs near you. Our HIV & Youth article covers the full landscape of services and challenges.

Significantly. Florida is one of the 10 states that has not expanded Medicaid under the Affordable Care Act. This creates a “coverage gap” — a group of people who make too much for traditional Medicaid but too little to qualify for ACA marketplace subsidies. The gap disproportionately hits people living with HIV.

The gap in numbers: to qualify for traditional Medicaid in Florida as an adult, you generally must be disabled, pregnant, or a parent of a minor child with very low income (roughly under 32% of federal poverty level for parents — about $8,500/year for a family of three). ACA marketplace subsidies kick in at 100% FPL. If you’re a childless adult earning between $0 and $15,060/year, you fall into the coverage gap and qualify for nothing.

How Ryan White fills the gap — but not completely: Ryan White Part B and ADAP cover HIV meds and outpatient HIV care for many people in the coverage gap. But Ryan White is legally not a health insurance program — it doesn’t cover unrelated medical care (a broken leg, surgery, hospitalization for non-HIV issues). People in the coverage gap living with HIV often have their HIV care covered but face medical bankruptcy if anything else happens.

Compared to Medicaid expansion states: a person with the same income and same HIV status in Kentucky, Ohio, or California gets full Medicaid coverage — HIV care, primary care, mental health, hospitalizations. Florida’s non-expansion means Florida PLHIV are more likely to skip preventive care, delay ER visits, and file medical bankruptcy.

What advocates are doing: the Florida Decides amendment campaign is working to put Medicaid expansion on the ballot. AIDS United, NASTAD, and Florida HIV advocates continue to lobby the legislature. If you want to plug in, contact your local AIDS Service Organization.

Fewer places than there used to be — but they exist. Florida’s 2023 restrictions on gender-affirming care (SB 254) severely limited services for both minors and adults, and Florida’s ban on Medicaid coverage of gender-affirming care was upheld in 2024. The effect on trans people living with HIV — a group at extremely high risk of losing care — has been significant.

Where trans HIV care is still available in Florida:

• Miami-Dade — Care Resource, Empower U, Pridelines have or refer to trans-affirming primary care coordinated with HIV care
• Broward County — Compass Community Center (Lake Worth) offers trans health services and referrals
• Orlando — The LGBT+ Center Orlando, Miracle of Love, and some Orange County health department clinics
• Tampa Bay — Metro Inclusive Health (St. Petersburg) operates trans-affirming primary and HIV care under one roof — one of the largest programs in the Southeast
• Jacksonville — JASMYN and Northeast Florida AIDS Network

What to look for in a provider: WPATH-informed care; willingness to work with your HIV provider directly on hormone-antiretroviral interactions (most modern regimens are compatible with feminizing and masculinizing hormones with minimal adjustment); sliding-scale fees or Ryan White-adjacent programs.

What Ryan White will and won’t cover: Ryan White can pay for primary care, mental health, and prescriptions for HIV-related care. It cannot pay for gender-affirming surgery. It can pay for hormones when prescribed alongside HIV care in most cases.

Cross-state and telehealth options: some Florida trans patients travel to Georgia or Alabama for hormones, or use telehealth providers like Plume or FOLX. Check whether these accept your Ryan White plan.

Gay and bisexual men — and other men who have sex with men (MSM) — account for roughly 67–70% of new HIV diagnoses in the U.S. each year, despite representing a small share of the overall population (see CDC HIV data). Understanding why means looking at both biology and structure.

Biology: Receptive anal sex carries a higher per-act transmission risk than other sexual routes. This isn’t a moral fact — it’s anatomy. The rectal lining is thinner and more vulnerable to HIV than vaginal tissue.

Network effects: HIV prevalence within sexual networks matters enormously. When prevalence is higher inside a network, the odds that any given partner is living with HIV are higher — even with the same number of partners as someone in a lower-prevalence network.

Structural factors: Decades of stigma, criminalization, and healthcare discrimination have created real barriers to testing, PrEP access, and care for gay and bisexual men — particularly men of color. Internalized homophobia and HIV stigma compound those barriers.

The tools to dramatically reduce HIV in gay and bisexual communities already exist — PrEP, U=U, regular testing, treatment. The gap is access, awareness, and the structural conditions that make those tools harder to reach for some men than others.

Black Americans represent about 13% of the U.S. population but account for roughly 40% of new HIV diagnoses (CDC) — a disparity that has persisted for decades and reflects the depth of structural inequality in American healthcare.

Black gay and bisexual men face the highest HIV rates of any subgroup in the country. Black women are disproportionately affected relative to women of other races. And in the South — where HIV rates are already the highest in the U.S. — Black communities carry a particularly heavy burden.

The drivers are structural, not behavioral: Black Americans face greater barriers to HIV testing, PrEP access, and HIV care — driven by poverty, lack of insurance, medical mistrust rooted in documented historical abuses, geographic healthcare deserts, and the compounding effects of housing instability and incarceration. The disparity cannot be explained by differences in sexual behavior.

Closing this gap requires culturally competent care, community-led outreach, structural investment in Black health, and an honest national reckoning with the role racism plays in public health outcomes.

Latino people account for roughly 27% of new HIV diagnoses in the U.S. — disproportionate to their approximately 19% share of the total population. Latino gay and bisexual men are among the most affected subgroups nationally.

Key structural barriers driving the disparity:

Immigration status and fear: Undocumented people may avoid testing or care out of fear of exposure or deportation — even though HIV care and Ryan White services are available regardless of immigration status.

Language access: Limited English proficiency creates real barriers to navigating healthcare systems, understanding prevention options, and finding culturally appropriate support.

Cultural stigma: HIV stigma intersects with cultural expectations around masculinity, sexuality, and family in ways that can make disclosure and help-seeking especially hard. Machismo and stigma around same-sex behavior create specific barriers for Latino MSM.

Economic barriers: Higher rates of uninsurance and poverty in some Latino communities limit access to PrEP, regular testing, and HIV care.

Community health workers (promotoras), Spanish-language materials, and culturally grounded outreach have shown real effectiveness at reducing these barriers where they’ve been deployed.

Transgender women — particularly Black and Latina transgender women — face among the highest HIV rates of any population in the U.S. Estimates suggest HIV prevalence among transgender women is 14 to 49 times higher than in the general adult population. This is not explained by behavior — it’s explained by an extraordinary concentration of structural vulnerabilities stacked on top of each other.

Housing instability: Transgender people face extremely high rates of homelessness and housing discrimination, which drives some into survival sex work and makes it much harder to stay in HIV care.

Employment discrimination: Systematic exclusion from employment pushes many trans women — especially trans women of color — into economic precarity.

Healthcare discrimination: A lot of trans women have experienced discrimination or outright refusal of care from healthcare providers, creating lasting and rational distrust of medical systems.

Criminalization: Criminalization of sex work, and HIV exposure laws, disproportionately target trans women.

Hormone therapy interactions: Modern integrase-based ART regimens (Biktarvy, Dovato) generally don’t interact with gender-affirming hormone therapy — but that’s a conversation to have openly with a knowledgeable HIV provider.

Reducing HIV in transgender communities takes more than biomedical tools — it takes addressing the structural conditions that make those tools inaccessible in the first place.

HIV rates in U.S. prisons and jails are significantly higher than in the general population — estimated at 3 to 5 times higher. The intersection of HIV and incarceration is one of the most underreported drivers of the ongoing U.S. epidemic.

Why incarceration concentrates HIV: Prisons and jails disproportionately hold people from communities already heavily affected by HIV — Black and Latino men, people who inject drugs, people who have engaged in sex work. Incarceration disrupts HIV care and ART adherence for people already on treatment, sometimes with dangerous gaps in medication access during intake and transfer.

Inside facilities: Consensual and non-consensual sex happens inside correctional facilities, and most facilities don’t provide condoms or harm reduction tools. Tattooing with shared equipment adds transmission risk. PrEP is rarely available in U.S. correctional settings.

Re-entry: The period immediately after release from incarceration is one of the highest-risk moments for HIV transmission and for interruption of HIV care. People leaving prison often face housing instability, insurance gaps, and loss of medical continuity all at once.

The HIV-incarceration intersection is inseparable from racial inequity — given who is incarcerated in the U.S. at disproportionate rates, addressing HIV in correctional settings is a racial justice issue as much as a public health one.

Injection drug use is one of the primary routes of HIV transmission in the U.S. Sharing needles, syringes, or other injection equipment introduces blood directly into the bloodstream — one of the most efficient transmission routes for HIV.

People who inject drugs (PWID) account for roughly 7% of new HIV diagnoses annually in the U.S. — but that number understates the full picture, because injection drug use also intersects with sexual transmission, incarceration, housing instability, and limited healthcare access.

What reduces HIV among people who inject drugs: Syringe service programs (SSPs) reduce HIV transmission by up to 50% and connect people to treatment and recovery services. Oral PrEP reduces HIV risk from injection drug use by at least 74% when taken consistently. Naloxone access saves lives from overdose. Medications for opioid use disorder (buprenorphine, methadone) reduce injection drug use and improve HIV care engagement.

The barrier: Stigma around drug use is among the most intense in American culture — and it creates barriers to both harm reduction services and HIV care. The most effective public health response treats addiction as a health condition and meets people where they are, without judgment.

HIV risk isn’t distributed randomly — it concentrates at the intersection of multiple structural disadvantages. A Black transgender woman who is unhoused and involved in sex work faces a qualitatively different HIV risk landscape than any single one of those factors would suggest alone. That’s what intersectionality means in HIV: disadvantages don’t just add up, they multiply.

The mechanisms are concrete: poverty limits access to PrEP and regular testing. Housing instability makes consistent treatment nearly impossible. Criminalization of sex work or drug use creates fear of engaging with healthcare systems. Racial discrimination in healthcare creates distrust. Stigma around HIV, queerness, drug use, or sex work keeps people from seeking care.

When public health interventions are designed for one identity at a time — “gay men” or “Black communities” or “people who inject drugs” — they often miss the people most affected, who don’t fit cleanly into any single category. The most effective HIV interventions are designed around whole people and whole communities, not risk categories.

“Community-led” means the people most affected by HIV aren’t just the subjects of programs — they design, run, and shape them. This principle is embedded in the most effective HIV responses in history.

ACT UP proved in the 1980s that community organizing could force faster drug approvals and reshape clinical trial design. Ryan White-funded peer navigators — people living with HIV supporting newly diagnosed clients — work because shared experience builds trust that clinical encounters alone cannot. Syringe service programs run by people who have used drugs reach communities that public health departments can’t. Community health workers in Latino neighborhoods build bridges that English-only systems miss entirely.

The evidence is consistent: HIV interventions designed with and led by the communities they serve outperform top-down approaches. Not because lived experience replaces expertise — but because it completes it.

RiseUpToHIV itself is a product of this principle: built by a person living with HIV, for the communities most in need of accurate, shame-free information.

Indigenous and Native American communities face HIV rates that are largely invisible in mainstream conversation — but they matter. Indigenous people in the US have HIV diagnosis rates roughly 30% higher than non-Hispanic whites, according to CDC surveillance, and Indigenous communities face some of the largest gaps in the HIV care continuum.

The specific challenges:

• Underdiagnosis. Indigenous people are diagnosed later — often at AIDS-stage disease — because of limited testing access, especially in rural and reservation settings. Indian Health Service (IHS) HIV testing rates lag other federal health systems.
• Distance to care. Many reservations are hours from the nearest HIV specialist. IHS facilities often refer HIV care to outside providers, creating continuity gaps.
• Confidentiality concerns. In tight-knit tribal communities, going to the local clinic can feel like disclosure. This drives people out of care or into towns where they’re anonymous — sometimes hours away.
• Historical medical trauma. From forced sterilizations to research abuses, Indigenous communities have earned reason to be cautious of the medical system. Rebuilding trust in HIV care is generational work.
• Two-Spirit erasure. LGBTQ+ Indigenous people (many of whom identify as Two-Spirit) face intersecting HIV risk factors and often lack care that recognizes both identities.

Where care is happening well: the National Native HIV Network (nnhn.org) coordinates culturally-grounded HIV work across tribal nations. Some urban Indian health centers — Seattle Indian Health Board, First Nations Community HealthSource in Albuquerque, NARA NW in Portland — offer trauma-informed HIV care. IHS is expanding testing under the Ending the HIV Epidemic initiative.

In Florida: the Seminole Tribe of Florida and Miccosukee Tribe have their own health services. If you’re Indigenous, non-tribal, or urban Indian in Florida, most HIV care will come through Ryan White clinics — some of which have Indigenous outreach programs.

Yes — biologically, women who have receptive vaginal or front hole sex with an partner living with HIV face a meaningful per-exposure transmission risk, though lower than for receptive anal sex. The biology involves a larger mucosal surface area, and other STIs (which cause inflammation or lesions) can significantly increase risk.

Despite that biological vulnerability, women are dramatically underrepresented in HIV prevention research, and PrEP uptake among women who could benefit remains far lower than among gay and bisexual men. Awareness is a major barrier — many women don’t think of themselves as at risk for HIV.

Women account for roughly 18% of new HIV diagnoses in the U.S., with Black women disproportionately affected. With the same prevention tools available — PrEP, U=U, condoms — risk can be dramatically reduced or eliminated.

Yes — PrEP is approved and effective for cisgender women. One important nuance: the time to full protection for receptive vaginal or front hole sex is longer than for anal sex. Oral PrEP (Truvada or Descovy) takes roughly 21 days to reach protective levels in vaginal tissue, compared to about 7 days for rectal tissue.

Injectable PrEP is particularly promising for women. The PURPOSE 1 trial tested lenacapavir (twice-yearly injection, now sold as Yeztugo) specifically among cisgender women and adolescent girls in sub-Saharan Africa and found near-100% efficacy — zero infections in the lenacapavir arm. That was a landmark finding for HIV prevention in women.

Despite being approved and effective, PrEP remains massively underutilized among women who could benefit. If you’re at risk and haven’t discussed PrEP with a provider, it’s worth the conversation. Use our Florida care locator to find PrEP providers near you.

With proper care, pregnant people living with HIV give birth to healthy, without HIV babies every day. This is one of the most dramatic success stories in modern HIV medicine.

With effective ART during pregnancy and delivery — and antiretroviral prophylaxis for the newborn — the risk of parent-to-child transmission drops to below 1%. Before treatment was available, that risk was 25–30%.

Key steps: Start or continue ART right away — this is the single most important thing. Work with both an HIV specialist and an OB who has experience caring for pregnancies affected by HIV. Some specific ART medications are preferred or avoided during pregnancy based on safety data, so a regimen review is important. C-section is not automatically required — vaginal birth is safe when viral load is suppressed.

Breast/chest-feeding guidance has evolved too — in high-income settings with reliable formula access, formula feeding is generally recommended to eliminate any residual transmission risk. If breast/chest-feeding matters to you, ask your provider about the current shared-decision-making guidance, which now accommodates that choice in some cases with suppressed viral load and close monitoring.

Yes — research suggests women living with HIV may experience menopause earlier than peers without HIV, and that menopausal symptoms can be more pronounced. HIV-related inflammation affects hormonal systems, and the intersection of menopause and HIV creates unique health considerations that are underresearched and often undertreated.

Hormone replacement therapy (HRT): Some older ART drugs (particularly certain NNRTIs and protease inhibitors) can interact with hormone levels in HRT. Modern integrase-based regimens (Biktarvy, Dovato, Triumeq) have far fewer interactions — but always review your ART and HRT together with your HIV provider.

Bone health: Menopause and HIV both independently increase osteoporosis risk. The combination warrants earlier bone density screening and active management.

Cardiovascular risk: Menopause elevates cardiovascular risk, which adds to HIV’s already-elevated cardiovascular risk. Proactive monitoring and statin consideration (per the REPRIEVE trial) are especially important for older women living with HIV.

If your HIV provider doesn’t regularly address menopause-specific health, raise it directly — this is an area where patient advocacy often drives better care.

Multiple factors compound each other:

The research gap: Many early HIV clinical trials enrolled primarily gay men. Drug dosing, side effect profiles, and efficacy data from those trials may not apply equally to women — yet women were often treated according to those data anyway. This is slowly changing, but the legacy persists.

Delayed diagnosis: HIV is still widely perceived as a “gay man’s disease.” Women are less likely to be tested proactively, and symptoms are sometimes attributed to other causes. Later diagnosis means worse outcomes.

Structural barriers: Women living with HIV are disproportionately Black, low-income, and often primary caregivers — factors that create real barriers to consistent care and to the time and space needed to prioritize their own health.

Intersecting stigma: HIV stigma compounds with stigma around gender, race, sexuality, and poverty in ways that make disclosure and help-seeking especially difficult for many women.

Closing these gaps requires not just clinical changes but structural ones: investment in women-centered HIV research, culturally competent care, and removal of the economic and social barriers that make treatment harder to access.

Yes. People living with HIV can plan pregnancies, conceive, and have healthy children. The best first step is a preconception conversation with an HIV provider and an OB or fertility clinician who understands HIV care.

Effective ART and a sustained undetectable viral load protect your health and make sexual HIV transmission impossible. During pregnancy and delivery, consistent HIV care reduces the chance of perinatal HIV transmission to less than 1% in settings with appropriate treatment and follow-up.

For mixed-status couples, the plan may include U=U, PrEP for the partner without HIV if they want that extra layer, timing intercourse, or fertility support. Your family goals belong in the conversation from the beginning.

Yes, and the options are expanding. For years, PrEP research and marketing focused almost entirely on men who have sex with men, and cisgender women were left with less evidence and fewer choices. That’s changing.

PrEP options that work for cisgender women in 2026:

• Truvada (F/TDF), daily pill — proven effective for cisgender women when taken daily. Requires 21 days of consistent use to reach maximum protection in vaginal tissue (versus 7 days for anal tissue).
• Apretude (cabotegravir), injectable every 2 months — FDA-approved for cisgender women in 2021. The HPTN 084 trial in African women showed 89% greater effectiveness than daily oral Truvada, largely because it eliminates adherence variability.
• Lenacapavir (Yeztugo), injectable every 6 months — approved 2025 for HIV prevention. The PURPOSE 1 trial in cisgender women in South Africa and Uganda showed 100% efficacy (zero infections in over 2,000 participants).
• Dapivirine vaginal ring — approved by WHO in 2021, not FDA-approved in the US. Advocacy for US approval is ongoing.
• Descovy (F/TAF) — approved for many uses but not approved for people at risk from vaginal sex because of limited data. Not the right choice for cisgender women.

What women should know: vaginal tissue absorption differs from rectal tissue — daily adherence with Truvada matters more for you than for someone at risk from anal sex. Long-acting options (Apretude, lenacapavir) remove that adherence gap entirely and are increasingly available through Ryan White and ADAP.

If your provider says “PrEP isn’t really for women” — find a new provider. That guidance is a decade out of date.

The guidance has changed significantly. For over 30 years, the US recommendation was clear: mothers living with HIV should not breastfeed. That changed in January 2023, when the DHHS Perinatal HIV Clinical Guidelines were updated to support informed choice.

What the current DHHS guidelines say:

• Mothers living with HIV who are on effective antiretroviral therapy with a sustained undetectable viral load throughout pregnancy can now be counseled about the option to breastfeed with less than 1% risk of transmission.
• Formula feeding remains the option with zero transmission risk and is still the safest choice.
• The decision is a shared one between the mother, her HIV provider, and her pediatrician — with informed consent about the residual risk.

Why the change: global data (particularly from studies in Africa where formula isn’t always safe or available) consistently showed transmission risk from breastfeeding by mothers on effective ART is very low. The mental health, bonding, and health benefits of breastfeeding are real. Stigma around not breastfeeding disproportionately affected Black women, immigrant women, and women in communities where breastfeeding is culturally expected.

What increases risk if breastfeeding: viral load blips or rebound during breastfeeding (need to monitor monthly). Mixed feeding — formula plus breast milk — is actually worse than exclusive breastfeeding because it can irritate the infant gut. Cracked nipples or mastitis; infant thrush or oral wounds.

What Florida providers are doing: most Florida HIV/OB coordinated care programs now offer breastfeeding as an informed-choice option. Miami-Dade, Broward, and Orange County programs have adopted the new guidelines. If your provider tells you outright “no, you can’t breastfeed” without offering the informed-choice conversation, ask for a referral to an HIV specialist familiar with the 2023 update.

The term “long-term survivor” (LTS) usually refers to people who have been living with HIV for a decade or more — though in the HIV community it often specifically honors those who survived the pre-treatment era, having been diagnosed in the 1980s or early 1990s when AIDS was nearly always fatal.

Surviving the early epidemic took extraordinary luck, community, and in many cases access to experimental treatments before they were approved. A lot of long-term survivors lost most or all of their peers to AIDS. The experience of having survived while others didn’t creates a specific kind of grief and complexity that doesn’t simply go away because treatment improved.

The term is also used more broadly today for anyone who has navigated decades with HIV — including people diagnosed in the 1990s or 2000s who have lived through significant medical, social, and personal changes around HIV.

Survivor’s guilt — the complex, often painful feeling of having survived when others around you didn’t — is one of the defining emotional experiences of many long-term HIV survivors who lived through the pre-treatment era.

For people diagnosed in the late 1980s or early 1990s, surviving often meant watching friends, partners, and entire community networks die in rapid succession. By the time effective treatment arrived in 1996, many survivors had attended dozens or hundreds of funerals. Some had written their own wills expecting not to survive.

Survivor’s guilt isn’t simple grief — it often includes guilt about having survived at all, complicated feelings about why some people accessed treatment or responded to it while others didn’t, and the particular weight of carrying the memory of people whose deaths went largely unwitnessed by the broader public.

This is real, ongoing trauma — not something that resolves because treatment worked. Therapy, peer community (including The Reunion Project), and intergenerational connection within the HIV community can help carry it.

Living well with HIV after two decades means staying ahead of a set of health risks that compound over time. After 20+ years, monitoring becomes as important as treatment itself.

Cardiovascular: HIV’s chronic inflammation accelerates cardiovascular disease. Ask your provider annually about your cardiovascular risk picture — and whether statin therapy makes sense for you (the REPRIEVE trial changed the standard here).

Bone density: Years of HIV and some ART exposure can affect bone density. DEXA screening after 50, or earlier with risk factors, is standard of care.

Neurocognitive health: HIV-associated neurocognitive disorder (HAND) exists on a spectrum. Mild cognitive changes are common in long-term survivors and warrant monitoring — especially if the people close to you are noticing them.

Polypharmacy: People aging with HIV often take multiple medications — HIV drugs plus drugs for other conditions. Drug interactions become a real concern. An HIV-knowledgeable pharmacist review of your full medication list every year or two is genuinely valuable.

Cancer screening: Particularly anal cancer for MSM (annual anal Pap if high-risk), cervical cancer for women (per guidelines), and liver cancer for anyone with a history of HCV coinfection.

Mental health: Ongoing depression, anxiety, and social isolation are significantly more common in older people living with HIV. Don’t let this be the afterthought in your annual care.

HAND is a spectrum of cognitive changes — memory issues, slower processing, trouble concentrating, mood changes — that can affect people who’ve lived with HIV for many years, especially those who acquired HIV before effective treatment was available (before 1996).

The three levels:

• Asymptomatic Neurocognitive Impairment (ANI) — measurable on cognitive testing but doesn’t interfere with daily life. Most common.
• Mild Neurocognitive Disorder (MND) — noticeable interference with complex tasks (managing meds, finances, work).
• HIV-Associated Dementia (HAD) — severe. Now rare in the modern treatment era.

Prevalence: studies find 30–50% of long-term survivors show some measurable cognitive changes on formal testing. Most cases are the asymptomatic form. Severe HAD is now rare because of effective ART.

What causes it: chronic low-level HIV activity in the brain (the blood-brain barrier limits how much medication reaches brain tissue), chronic inflammation from decades of immune activation, cardiovascular risk factors, overlap with normal aging, and depression.

What helps: staying on effective ART with strong CNS penetration (your provider can adjust if needed), managing cardiovascular risk factors, regular aerobic exercise, sleep hygiene, mental health support (untreated depression looks a lot like HAND), and cognitive engagement — reading, socializing, learning new skills.

When to talk to your provider: new or worsening forgetfulness that interferes with daily life, getting lost in familiar places, difficulty managing medications or finances you used to handle easily, or family noticing changes.

A key distinction: normal aging includes some cognitive slowing, and depression is extremely common in long-term survivors and often looks like HAND. A proper workup can distinguish among these — and depression is very treatable.

ACT UP (AIDS Coalition to Unleash Power) was founded in New York in March 1987 and became the most influential HIV/AIDS activist organization in history. At a time when thousands were dying and the government was largely silent, ACT UP used direct action — die-ins, protests at the FDA, disruption of Catholic Mass at St. Patrick’s Cathedral, demonstrations on Wall Street — to demand faster drug approvals, affordable treatment, and political accountability.

ACT UP’s impact was concrete: they changed how the FDA approves drugs, helped create expanded access programs, put treatment activists inside clinical trial design, and broke open the closed world of pharmaceutical research to the people dying from the disease being studied.

The phrase “drugs into bodies” — and the principle that people with a disease have the right to participate in decisions about its treatment — came from ACT UP. Every HIV advocacy organization working today stands on what they built.

The Reagan administration’s failure to respond to the AIDS crisis is one of the most documented public health failures in American history. Reagan did not publicly say the word “AIDS” in a major speech until 1987 — six years into the epidemic, after more than 25,000 Americans had died.

The reasons were largely political and moral: the epidemic initially hit communities — gay men, people who inject drugs, Haitian immigrants — that the Reagan administration and much of the American public were willing to dismiss or condemn. The epidemic was framed as a consequence of behavior rather than a public health emergency.

The result was years of lost time: delayed research funding, no public education, no federal leadership, and a body count that could have been far lower. The communities most affected organized themselves to survive — and in doing so built the infrastructure of HIV advocacy that still exists today.

The turning point was 1996. The introduction of protease inhibitors and the advent of combination antiretroviral therapy — what was then called “the cocktail” or HAART — transformed HIV from a near-certain death sentence into a manageable chronic illness almost overnight.

People who had been expected to die began returning to work. AIDS wards started to empty. Death rates plummeted. It was one of the most dramatic reversals in the history of medicine — and it happened because of a combination of accelerated science (pushed by activist pressure) and new drug mechanisms that could suppress HIV in ways AZT alone could not.

1996 also produced the first evidence connecting viral load suppression to survival — the science that eventually led to U=U two decades later.

One of the most underappreciated stories of the AIDS crisis is the enormous role lesbian women played — at a time when their own community was not the primary target of the epidemic.

Lesbians showed up in extraordinary numbers: as caregivers for dying gay men, as ACT UP activists, as blood donors (at a time when gay men were banned from donating), as organizers of fundraisers and meal deliveries for people too sick to care for themselves, and as founders of many of the AIDS service organizations that still exist today.

This solidarity came despite real tensions between gay men and lesbian women in the broader LGBTQ+ politics of the era. It’s a story of community across difference — and one that is finally getting more of the historical recognition it deserves.

Ryan White was a teenager from Kokomo, Indiana who was diagnosed with AIDS in 1984 after contracting HIV through a contaminated blood factor product used to treat his hemophilia. He was 13 years old.

When Ryan tried to return to his middle school, he was banned based on fear and stigma. His family sued — and won — but the fight was long, public, and brutal. His family faced harassment, their home was targeted, and Ryan himself became a national symbol of the injustice of AIDS stigma.

Ryan White became an activist, appeared before Congress, and befriended celebrities including Elton John and Michael Jackson, bringing a human face to the epidemic at a time when most of America was looking away. He died in April 1990 at 18 years old, just months before the federal legislation bearing his name was signed into law.

The Ryan White CARE Act — now the Ryan White HIV/AIDS Program — has been the cornerstone of the federal HIV safety net ever since.

The HIV epidemic produced one of the most remarkable outpourings of artistic response in modern history — born from grief, rage, solidarity, and the urgent need to bear witness to what was happening when mainstream culture refused to look.

The AIDS Memorial Quilt, begun in 1987, grew into one of the largest pieces of community folk art in the world — a memorial to individual lives lost that now includes over 50,000 panels and was nominated for the Nobel Peace Prize.

Visual artists like Keith Haring and David Wojnarowicz made HIV a subject of public art before it was acceptable to discuss. Gran Fury, the ACT UP art collective, created some of the most powerful public health messaging ever produced — including the iconic “Silence = Death” poster.

Literature, theater, and film followed: Tony Kushner’s Angels in America, Larry Kramer’s The Normal Heart, and dozens of other works gave voice to a community that the mainstream was actively trying to ignore.

Hart Island is a small island off the Bronx that has served as New York City’s potter’s field — its burial ground for the unclaimed and unidentified dead — since 1869. During the height of the AIDS crisis in the 1980s and early 1990s, it became the burial place for hundreds of people who died of AIDS-related illness, many of whom had been abandoned by their families or died with no one to claim them.

For years, Hart Island was operated by the Department of Correction using prison labor, and family members were restricted from visiting the graves of their loved ones. It became a symbol of the abandonment and erasure of people who died of AIDS-related illness — buried in mass graves on a remote island, inaccessible even in death.

Advocacy eventually forced changes: Hart Island is now managed by the NYC Parks Department, and access for families has improved. It remains a place of profound grief and historical reckoning for the AIDS community.